0001437749-22-007725 | 10-K | XBRL Viewer

Other Current Assets [Text Block]

D.	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

	*December 31,*
	*2021*		*2020*
Prepaid insurance	$	637	$	453
Prepaid offering costs		293		825
Other prepaid expenses and current assets		252		203
Total prepaid expenses and other current assets	$	1,182	$	1,481

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (8,555,000)	$ (12,760,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Loss on extinguishment of debt	16,096,000	0
Stock-based compensation expense	2,436,000	2,491,000
Non-cash interest expense	8,000	4,741,000
Amortization of debt issuance costs and debt discount	150,000	2,305,000
Depreciation and amortization expense	257,000	273,000
Fair value adjustment related to derivative and warrant liability	26,000	184,000
Loss on sublease and disposal of property and equipment	76,000	251,000
Consulting fees paid in common stock	302,000	202,000
Change in assets and liabilities:
Accounts and other receivables	1,051,000	(714,000)
Prepaid expenses and other assets	(825,000)	160,000
Operating lease right-of-use assets	133,000	128,000
Accounts payable and accrued expenses	(1,113,000)	931,000
Operating lease liabilities	(326,000)	(271,000)
Other liabilities	723,000	140,000
Net cash provided by (used in) operating activities	10,439,000	(1,939,000)
Cash flows from investing activities:
Purchases of property and equipment	(102,000)	(33,000)
Purchases of long-term investments	(15,422,000)	0
Net cash used in investing activities	(15,524,000)	(33,000)
Cash flows from financing activities:
Proceeds from Public Offering, net of discounts and commissions	49,285,000	0
Payment to repurchase shares as part of the Share Repurchase Program	(2,814,000)	0
Proceeds from equity line of credit	0	2,303,000
Proceeds from Payment Protection Program loan	0	781,000
Payment of offering costs	(1,338,000)	(84,000)
Repayment of principal on finance lease liabilities	(173,000)	(227,000)
Payment of debt issuance costs	(2,881,000)	(34,000)
Repayment of principal on convertible notes	(37,924,000)	0
Net proceeds from exercise of common stock warrants	30,819,000	0
Net cash provided by financing activities	113,109,000	2,739,000
Net increase in cash, cash equivalents and restricted cash	108,024,000	767,000
Cash, cash equivalents and restricted cash, beginning of year	4,322,000	3,555,000
Cash, cash equivalents, end of year	112,346,000	4,322,000
Supplemental cash flow information:
Cash paid for interest	218,000	78,000
Commitment shares issued in connection with equity line of credit included in deferred offering costs	0	121,000
Amounts due for property and equipment included in accounts payable and accrued expenses	0	4,000
Amounts due for deferred offering costs included in accounts payable and accrued expenses	48,000	817,000
Cash paid in lieu of fractional shares in connection with 16-for-1 reverse stock split included in accounts payable and accrued expenses	0	23,000
Property and equipment financed under a lease agreement	0	17,000
Fair value of warrants issued to underwriters in connection with Public Offering	3,485,000	0
Conversion of Facility Notes into Series B-2 Preferred Stock [Member]
Supplemental cash flow information:
Notes principal converted	31,477,000	0
The 2019 Notes Converted to Common Stock [Member]
Supplemental cash flow information:
Notes principal converted	0	15,863,000
Warrants Issued in Connection with January 2021 Inducement Transaction [Member]
Cash flows from financing activities:
Proceeds from Inducement Transaction, net of discounts and commissions	41,384,000	0
Warrants Issued in Connection with June 2021 Inducement Transaction [Member]
Cash flows from financing activities:
Proceeds from Inducement Transaction, net of discounts and commissions	$ 36,751,000	$ 0

Note C - Accounts and Other Receivables - Accounts and Other Receivables (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	*December 31,*
	*2021*		*2020*
Accounts receivable	$	1,421	$	2,442
Other receivables		107		137
Total accounts and other receivables	$	1,528	$	2,579

Note O - Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	*December 31,*
	*2021*		*2020*
Conversion of Deerfield Convertible Note		-		81,101
Conversion of January 2020 Note		-		34,615
Conversion of December 2019 Notes		-		625,747
Outstanding awards under equity incentive plans		1,273,879		355,785
Outstanding common stock warrants		4,221,350		151,442
Total securities excluded from the calculation of weighted average number of shares of common stock outstanding		5,495,229		1,248,690

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	December 31,
	2021			2020
Basic net loss per share of common stock:

Net loss	$	(8,555	)	$	(12,760	)
Less: Dividends declared or accumulated		(54,342	)		-
Net loss attributable to common stockholders	$	(62,897	)	$	(12,760	)
Less: Net loss attributable to participating securities		-			-
Undistributed net loss attributable to shares of common stockholders, basic	$	(62,897	)	$	(12,760	)
Weighted average number of shares of common stock outstanding, basic		29,766			3,981
Basic net loss attributable to common stockholders per share of common stock	$	(2.11	)	$	(3.21	)

Diluted net loss per share of common stock:

Undistributed net loss attributable to common stockholders	$	(62,897	)	$	(12,760	)
Less: Fair value adjustment income related to KVK Warrant liability		(26	)		-
Undistributed net loss attributable to common stockholders, diluted	$	(62,923	)	$	(12,760	)
Weighted average number of shares of common stock outstanding, basic		29,766			3,981
Dilutive effect of KVK Warrant		0			-
Weighted-average number of shares of common stock outstanding, diluted		29,766			3,981
Diluted loss attributable to common stockholders per share of common stock	$	(2.11	)	$	(3.21	)

Note M - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance as of beginning of period	$ 255	$ 96
Adjustment to fair value	51	159
Balance as of end of period	$ 306	$ 255

Note B - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Significant Accounting Policies [Text Block]

B.	Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases, and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of long-term investments and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit and investments with multiple financial institutions, the balances of which frequently exceed insured limits, and accounts receivable, which are concentrated amongst a limited number of customers.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash equivalents.

Long-term Investments

The Company maintains investment securities that are classified as trading securities. These securities are carried at fair value with unrealized gains and losses included in other (expense) income on the statements of operations. The securities primarily consist of certificates of deposit, U.S. Treasury securities and U.S. government-sponsored agency securities. As of December 31, 2021, the Company held long-term investments with an aggregate fair value of $15.4 million that contained aggregate unrealized losses of $13,000. These long-term investments have been in a continuous unrealized loss position for less than 12 months and the Company expects these investments to fully recover prior to their maturity. The unrealized losses are primarily driven by interest rate changes and are not credit related. The Company had no long-term investments as of December 31, 2020.

Property and Equipment

The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to ten years. Leasehold improvements are amortized over the shorter of the useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in the statements of operations.

Debt Issuance Costs

Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method.

Offering Costs

Offering costs incurred in connection with capital offering arrangements are recorded as deferred offering costs in prepaid expenses and other currents assets on the balance sheet. Once the offering arrangement closes the deferred offering costs are reclassified as a reduction of the related net proceeds of the offering in additional paid-in capital on the balance sheet. If it's a continuous offering the deferred offering costs are amortized over the life of the respective offering arrangement using a pro-rata method which matches the costs to the funds raised from the offering. If the continuous offering arrangement terminates prior to all the deferred offering costs being recognized the deferred offering costs are written off and expensed in general and administrative expense on the statement of operations.

Supply Arrangements

The Company enters into supply arrangements for the supply of components of its products and product candidates. These arrangements also may include a share of future revenue if related products or product candidates reach commercialization. Costs under these supply arrangements, if any, are expensed as incurred (Note I).

Impairment of Long-Lived Assets

Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying values, an impairment loss is recorded for the difference between the carrying values and fair values of the asset. No such impairment occurred for the years ended December 31, 2021, or 2020 .

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

●

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

●

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

●

Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Revenue Recognition

The Company commenced recognizing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers (“ASC 606”), starting January 1, 2018.

Arrangements with Multiple-Performance Obligations

From time to time, the Company enters into arrangements for research and development, manufacturing and/or commercialization services. Such arrangements may require the Company to deliver various rights, services, including intellectual property rights/licenses, research and development services, and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, consulting fees and/or profit sharing.

In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.

The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.

Licensing Agreements

The Company enters into licensing agreements with licensees that fall under the scope of ASC 606.

The terms of the Company’s licensing agreements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in licensing revenues.

As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as, independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probability of regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the licensee which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

Up-front Fees: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.

Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the licensee’s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the licensee’s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company’s estimate of the transaction price may also result in negative licensing revenues and earnings in the period of adjustment.

KP415 License Agreement

In September 2019, the Company entered into a Collaboration and License Agreement (the “KP415 License Agreement”) with Commave Therapeutics SA, an affiliate of Gurnet Point Capital (“Commave”). Under the KP415 License Agreement, the Company granted to Commave an exclusive, worldwide license to develop, manufacture and commercialize the Company’s product candidates containing SDX and d-methylphenidate (“d-MPH”), including AZSTARYS, KP484, and, at the option of Commave, KP879, KP922 or any other product candidate developed by the Company containing SDX and developed to treat ADHD or any other CNS disorder (the “Additional Product Candidates” and, collectively with AZSTARYS and KP484, the “Licensed Product Candidates”). Pursuant to the KP415 License Agreement, Commave (i) paid the Company an upfront payment of $10.0 million; (ii) agreed to pay milestone payments of up to $63.0 million upon the occurrence of specified regulatory milestones related to AZSTARYS and KP484; (iii) agreed to pay additional payments of up to $420.0 million upon the achievement of specified U.S. sales milestones; and (iv) has agreed to pay the Company quarterly, tiered royalty payments ranging from a percentage in the high single digits to the mid-twenties of Net Sales (as defined in the KP415 License Agreement) in the United States and a percentage in the low to mid-single digits of Net Sales in each country outside the United States, in each case subject to specified reductions under certain conditions as described in the KP415 License Agreement. Commave is obligated to make such royalty payments on a product-by-product basis until expiration of the royalty term for the applicable product.

In April 2021, the Company entered into Amendment No. 1 to the KP415 Amendment (the "KP415 Amendment"). Pursuant to the KP415 Amendment, the Company and Commave agreed to modify the compensation terms of the KP415 License Agreement. Pursuant to the KP415 Amendment, Commave paid the Company $10.0 million in connection with the entry into the KP415 Amendment as a result of the regulatory approval of AZSTARYS in the United States which occurred on March 2, 2021. Commave also paid the Company $10.0 million following the receipt of the scheduling determination of the compound SDX by the U.S. Drug Enforcement Agency (the "DEA"), which occurred on May 7, 2021. In addition, the KP415 Amendment increased the total remaining future regulatory and sales milestone payments related to AZSTARYS to up to an aggregate of $590.0 million in payments upon the occurrence of specified regulatory milestones related to AZSTARYS and upon the achievement of specified U.S. net sales milestones. Further, under the KP415 Amendment, Commave agreed to pay the Company quarterly, tiered royalty payments that are calculated from a base royalty rate percentage in the high single digits to the mid-twenties of net sales in the United States, subject to adjustment based on annual net sales, and a percentage in the low to mid-single digits of Net Sales in each country outside the United States, in each case subject to specified reductions under certain conditions, including with respect to the final approval label, as described in the KP415 License Agreement. Commave is obligated to make such royalty payments on a product-by-product basis until expiration of the royalty term for the applicable product.

Pursuant to the KP415 Amendment, Commave and the Company also agreed to modify Commave’s ROFR such that the Company’s product candidate, KP922, is no longer subject to Commave’ ROFR to acquire, license or commercialize any Additional Product Candidate. Commave’s ROFR shall only apply to any Additional Product Candidate which contains SDX, with such ROFR expiring upon the acceptance of an NDA for such Additional Product Candidate containing SDX.

Commave also agreed to be responsible for and reimburse the Company for all of the development, commercialization and regulatory expenses incurred on the licensed products, subject to certain limitations as set forth in the KP415 License Agreement. As part of this agreement the Company is obligated to perform consulting services on behalf of Commave related to the licensed products. For these consulting services, Commave has agreed to pay the Company a set rate per hour on any consulting services performed on behalf of Commave for the benefit of the licensed products.

In accordance with the terms of the Company’s March 20, 2012 Termination Agreement with Aquestive Therapeutics (formerly known as MonoSol Rx, LLC), Aquestive Therapeutics has the right to receive an amount equal to 10% of any royalty or milestone payments made to the Company related to AZSTARYS, KP484, KP879 or KP1077 under the KP415 License Agreement.

The KP415 License Agreement is within the scope of ASC 606, as the transaction represents a contract with a customer where the participants function in a customer / vendor relationship and are not exposed equally to the risks and rewards of the activities contemplated under the KP415 License Agreement. Using the concepts of ASC 606, the Company identified the grant of the exclusive, worldwide license and the performance of consulting services, which includes the reimbursement of out-of-pocket third-party research and development costs, as its only two performance obligations at inception. The Company further determined that the transaction price, at inception, under the agreement was $10.0 million upfront payment plus the fair value of the Development Costs (as defined in the KP415 License Agreement) which was allocated among the performance obligations based on their respective related stand-alone selling price.

The consideration allocated to the grant of the exclusive, worldwide license was $10.0 million, which reflects the standalone selling price. The Company utilized the adjusted market assessment approach to determine this standalone selling price which included analyzing prospective offers received from various entities throughout our licensing negotiation process as well as the consideration paid to other competitors in the market for a similar type of transaction. The Company determined that the intellectual property licensed under the KP415 License Agreement represented functional intellectual property and it has significant standalone functionality and therefore should be recognized at a point in time as opposed to over time. The revenue related to the grant of the exclusive, worldwide license was recognized at a point in time at the inception of the KP415 License Agreement.

The consideration allocated to the performance of consulting services, which includes the reimbursement of out-of-pocket third-party research and development costs, was the fair value of the Development Costs (as defined in the KP415 License Agreement), which reflects the standalone selling price. The Company utilized a blended approach which took into consideration the adjusted market assessment approach and the expected cost plus a margin approach to determine this standalone selling price. This blended approach utilized the adjusted market approach and expected cost plus margin approach to value the performance of consulting services which included analyzing hourly rates of vendors in the market who perform similar services to those of the Company to develop a range and then analyzing the average cost per hour of our internal resources and applying a margin which placed the value in the median of the previously identified range. For the reimbursement of out-of-pocket third-party research and development costs the Company utilized the expected cost plus a margin approach, which included estimating the actual out-of-pocket cost the Company expects to pay to third-parties for research and development costs and applying a margin, if necessary. The Company determined that no margin was necessary for these out-of-pocket third-party research and development costs as these are purely pass-through costs and the margin for managing these third-party activities is included within the value of the performance of consulting services. The Company determined that the performance of consulting services, including reimbursement of out-of-pocket third-party research and development costs, is a performance obligation that is satisfied over time as the services are performed and the reimbursable costs are paid. As such, the revenue related to the performance obligation will be recognized as the consulting services are performed and the services associated with the reimbursable out-of-pocket third-party research and development costs are incurred and paid by the Company, in accordance with the practical expedient allowed under ASC 606 regarding an entity’s right to consideration from a customer in an amount that corresponds directly to the value to the customer of the entity’s performance completed to date. As discussed above, the combination of the standalone selling price of these consulting services and certain out-of-pocket third-party research and development costs for AZSTARYS was the fair value of the Development Costs at inception. These Development Costs effectively created a cap on certain consulting services and out-of-pocket third-party research and development costs identified in the initial product development plan for AZSTARYS which was anticipated at the inception date of the KP415 License Agreement. As of December 31, 2020, the Company had recognized all of the consulting services and out-of-pocket third-party research and development costs under this cap.

Under the KP415 License Agreement, Commave was granted an exclusive right to first negotiation whereby upon completion of a Phase 1 proof-of-concept study, the Company and Commave may negotiate the economic terms under which certain Additional Products may be included as a Product (both as defined in the KP415 License Agreement) under the KP415 License Agreement (the “Additional Product Option”). In addition to the Additional Product Option, Commave was also granted a right of first refusal (“ROFR”) to acquire, license and/or commercialize any of the Additional Product Candidates should they choose not to exercise the Additional Product Option. Should Commave choose to exercise the Additional Product Option on any Additional Product Candidates, Commave and the Company shall negotiate in good faith regarding the economic terms of such Additional Product Candidate. Further, should Commave exercise the ROFR on any Additional Product Candidate, the economic terms of the agreement shall be the same as those offered to the third-party. Under ASC 606 an option to acquire additional goods or services gives rise to a performance obligation if the option provides a material right to the customer. The Company concluded that the above-described Additional Product Option and ROFR do not constitute material rights to the customer as Commave would acquire the goods or services at a to be negotiated price, which the Company expects to approximate fair value and therefore Commave would not receive a material discount on these goods or services compared to market rates.

The Company is entitled to additional payments from Commave conditioned upon the achievement of specified regulatory milestones related to AZSTARYS and KP484 and the achievement of certain U.S. sales milestones. Further, Commave will pay the Company quarterly, tiered royalty payments ranging from a percentage in the high single digits to mid-twenties of Net Sales (as defined in the KP415 License Agreement) in the United States and a percentage in the low to mid-single digits of Net Sales in each country outside of the U.S., in each case subject to specified reductions under certain conditions as described in the KP415 License Agreement. The Company concluded that these regulatory milestones, sales milestones and royalty payments each contain a significant uncertainty associated with a future event. As such, these milestone and royalty payments are constrained at contract inception and are not included in the transaction price as the Company could not conclude that it is probable a significant reversal in the amount of cumulative revenue recognized will not occur surrounding these milestone payments. At the end of each reporting period, the Company updates its assessment of whether the milestone and royalty payments are constrained by considering both the likelihood and magnitude of the potential revenue reversal.

For example, in May 2020, the FDA accepted the Company’s NDA for AZSTARYS. Per the KP415 License Agreement, the Company received a regulatory milestone payment of $5.0 million following the FDA’s acceptance of the AZSTARYS NDA. Since the FDA accepted the Company’s NDA for AZSTARYS the constraint was removed and revenue recognized. The associated revenue was allocated among the two performance obligations identified at contract inception. Since both performance obligations were satisfied as of the end of the second quarter of 2020 the full $5.0 million payment was recognized as revenue during the second quarter of 2020.

Per the KP415 Amendment, the Company earned a regulatory milestone payment of $10.0 million following the FDA’s approval of the AZSTARYS NDA, in March 2021, as well as $10.0 million following the DEA's scheduling of SDX in May 2021. Since the FDA approved the NDA for AZSTARYS and the DEA scheduled SDX, the constraints were removed and revenue recognized. The associated revenue was allocated among the two performance obligations identified at contract inception. Since both performance obligations were satisfied as of the end of each respective quarter of 2021, the full $10.0 million for each milestone was recognized as revenue in the statements of operations for the first quarter and second quarter of 2021, respectively. In accordance with ASC 340-40, Contracts with Customers, the Company recognized $1.0 million, respectively, of royalty costs due to payment to Aquestive related to the regulatory milestones earned and recorded it in the item titled royalty and direct contract acquisition costs in the statements of operations for first and second quarter of 2021.

For the years ended December 31, 2021, and 2020, the Company recognized revenue under the KP415 License Agreement of $20.9 million and $7.3 million, respectively. There was no deferred revenue related to this agreement as of December 31, 2021, or 2020.

Consulting Arrangements

The Company enters into consulting arrangements with third parties that fall under the scope of ASC 606. These arrangements may require the Company to deliver various rights, services, including research and development services, regulatory services and/or commercialization support services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of consulting fees and reimbursements of out-of-pocket third-party research and development, regulatory and commercial costs.

Corium Consulting Agreement

In July 2020, the Company entered into a consultation services arrangement (the “Corium Consulting Agreement”) with Corium, Inc. (“Corium”) under which Corium engaged the Company to guide the product development and regulatory activities for certain current and potential future products in Corium’s portfolio, as well as continue supporting preparation for the potential commercial launch of AZSTARYS (together, “Corium Consulting Services”). Corium is a portfolio company of Gurnet Point Capital and was tasked by Commave to lead all commercialization activities for AZSTARYS under the KP415 License Agreement, as discussed above.

Under the Corium Consulting Agreement, the Company is entitled to receive payments from Corium of up to $15.6 million, $13.6 million of which will be paid in quarterly installments through March 31, 2022. The remaining $2.0 million was conditioned upon the approval by the FDA of the NDA for Corium's product candidate, ADLARITY. This $2.0 million was earned in the first quarter of 2022. Corium also agreed to be responsible for and reimburse the Company for all development, commercialization and regulatory expenses incurred as part of the performance of the Corium Consulting Services.

The Corium Consulting Agreement is within the scope of ASC 606, as the transaction represents a contract with a customer where the participants function in a customer / vendor relationship and are not exposed equally to the risks and rewards of the activities contemplated under the Corium Consulting Agreement. Using the concepts of ASC 606, the Company identified the performance of consulting services, which includes the reimbursement to the Company of third-party pass-through costs, as its only performance obligation at inception. The Company further determined that the transaction price, at inception, under the agreement was $13.6 million which is the fair value of the consulting services, including the reimbursement of third-party pass-through costs. The Company concluded that the regulatory milestone contains a significant uncertainty associated with a future event. As such, this milestone is constrained at contract inception and is not included in the transaction price as the Company could not conclude that it is probable a significant reversal in the amount of cumulative revenue recognized will not occur surrounding these milestone payments. At the end of each reporting period, the Company updates its assessment of whether the milestone is constrained by considering both the likelihood and magnitude of the potential revenue reversal.

The Company determined that the performance of consulting services, including reimbursement of third-party pass-through costs, is a performance obligation that is satisfied over time as the services are performed and the reimbursable costs are paid. As such, the revenue related to the performance obligation will be recognized as the consulting services are performed and the services associated with the reimbursable third-party pass-through costs are incurred and paid by the Company, in accordance with the practical expedient allowed under ASC 606 regarding an entity’s right to consideration from a customer in an amount that corresponds directly to the value to the customer of the entity’s performance completed to date. As of December 31, 2021, the Company has recognized approximately 85% of the consulting services and third-party pass-through costs under the Corium Consulting Agreement.

For the years ended December 31, 2021, and 2020, the Company recognized revenue under the Corium Consulting Agreement of $7.7 million and $3.9 million, respectively. As of December 31, 2021, and 2020, the Company had deferred revenue related to this agreement of $0.4 million and $0.1 million, respectively.

Other Consulting Arrangements

For the years ended December 31, 2021, and 2020, the Company recognized revenue under other consulting arrangements of $0.1 million and $1.7 million, respectively. There was no deferred revenue from other consulting arrangements as of December 31, 2021, or 2020.

Accounts and Other Receivables

Accounts and other receivables consist of receivables under the KP415 License Agreement and Corium Consulting Agreement, as well as receivables related to other consulting arrangements, income tax receivables and other receivables due to the Company. Receivables under the KP415 License Agreement and Corium Consulting Agreement are recorded for amounts due to the Company related to reimbursable third-party costs and performance of consulting services. These receivables, as well as the receivables related to other consulting arrangements, are evaluated to determine if any reserve or allowance should be established at each reporting date. As of December 31, 2021, the Company had receivables related to the Corium Consulting Agreement of $1.2 million, KP415 License Agreement of $0.1 million and other consulting arrangements of $0.1 million. As of December 31, 2020, the Company had receivables related to the Corium Consulting Agreement of $2.1 million and other consulting arrangements of $0.4 million. As of December 31, 2021, and 2020, no reserve or allowance for doubtful accounts has been established.

Research and Development

Major components of research and development costs include cash compensation, stock-based compensation, depreciation and amortization expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Costs incurred in research and development are expensed as incurred.

The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the statements of operations as the Company receives the related goods or services.

The Company enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with the applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of the service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of the accrued expenses as of each balance sheet date based on the facts and circumstances known. The Company periodically confirms the accuracy of the estimates with the service providers and make adjustments, if necessary.

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative expenses on the statements of operations.

Income Taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. Valuation allowances are recorded to reduce deferred tax assets to the amount the Company believes is more likely than not to be realized.

Uncertain tax positions are recognized only when the Company believes it is more likely than not that the tax position will be upheld on examination by the taxing authorities based on the merits of the position. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. The Company did not have any accrued interest or penalties associated with uncertain tax positions as of December 31, 2021, and 2020.

The Company files income tax returns in the United States for federal and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal and state and local income tax examinations for years prior to 2015, although carryforward attributes that were generated prior to 2017 may still be adjusted upon examination by the Internal Revenue Service if used in a future period. No income tax returns are currently under examination by taxing authorities.

Stock-Based Compensation

The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers and directors based on the estimated fair values of the awards as of the grant date. The Company records the value of the portion of the award that is ultimately expected to vest as expense over the requisite service period. The Company also accounts for equity instruments issued to non-employees using a fair value approach under Accounting Standards Codification ("ASC") subtopic 505-50. The Company values equity instruments and stock options granted using the Black-Scholes option pricing model.

Basic and Diluted Net Loss per Share of Common Stock

The Company uses the two-class method to compute net loss per common share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock and select warrants are entitled to participate in distributions, when and if declared by the board of directors, that are made to common stockholders and, as a result, are considered participating securities.

Segment and Geographic Information

Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company views its operations and manages its business as a single operating and reporting segment. All assets of the Company were held in the United States as of December 31, 2021, and 2020.

Application of New or Revised Accounting Standards—Adopted

From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326)—Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This update applies to all entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial statements and disclosures.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820)—Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, Conceptual Framework for Financial Reporting—Chapter 8: Notes to Financial Statements, which the FASB finalized on August 28, 2018, including the consideration of costs and benefits. This update applies to all entities that are required, under existing U.S. GAAP, to make disclosures about recurring or nonrecurring fair value measurements. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The adoption of ASU 2018-13 did not have a material impact on the Company’s financial statements and disclosures.

Application of New or Revised Accounting Standards—Not Yet Adopted

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40); Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which addresses issues identified as a result of the complexities associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. This update addresses, among other things, the number of accounting models for convertible debt instruments and convertible preferred stock, targeted improvements to the disclosures for convertible instruments and earnings-per-share (“EPS”) guidance and amendments to the guidance for the derivatives scope exception for contracts in an entity’s own equity, as well as the related EPS guidance. This update applies to all entities that issue convertible instruments and/or contracts in an entity’s own equity. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. FASB specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company does not believe the adoption of ASU 2020-06 will have a material impact on the Company’s financial statements and disclosures.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40); Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the FASB Emerging Issues Task Force (“ASU 2021-04”), which aims to clarify and reduce diversity in issuer's accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. This update applies to all entities that issue freestanding written call options that are classified in equity. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. FASB specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company does not believe the adoption of ASU 2021-04 will have a material impact on the Company’s financial statements and disclosures.

Note H - Commitments and Contingencies - Supplement Balance Sheet Information Related to Lease (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
less: accumulated depreciation and amortization	$ (1,925)	$ (1,726)
Lease liabilities	21	194
Operating lease right-of-use assets	1,141	1,350
Total operating lease right-of-use assets	1,141	1,350
Current portion of operating lease liabilities	356	327
Operating lease liabilities, less current portion	1,232	1,587
Total operating lease liabilities	$ 1,588	$ 1,914
Finance leases (Year)	1 year	1 year
Operating leases (Year)	4 years	5 years
Finance leases	12.00%	8.50%
Operating leases	7.50%	7.50%
Property and Equipment, At Cost [Member]
Property and equipment, at cost	$ 1,031	$ 1,031
Accumulated Depreciation and Amortization [Member]
less: accumulated depreciation and amortization	(651)	(523)
Property and Equipment, Net [Member]
Property and equipment, net	380	508
Other Current Liabilities [Member]
Other current liabilities	15	172
Other Noncurrent Liabilities [Member]
Other long-term liabilities	6	22
Operating Lease Right-of-Use Assets [Member]
Operating lease right-of-use assets	1,141	1,350
Total operating lease right-of-use assets	1,141	1,350
Current Portion of Operating Lease Liabilities [Member]
Current portion of operating lease liabilities	356	327
Operating Lease Liabilities, Less Current Portion [Member]
Operating lease liabilities, less current portion	$ 1,232	$ 1,587

Note N - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	*Year ended December 31,*
	*2021*			*2020*
Federal statutory rate		21.00	%		21.00	%
Effect of:
Change in valuation allowance		(28.39	)		(22.65	)
Return to provision and deferred true-up		(0.26	)		0.11
Change in rate		3.00			0.82
State tax benefit (net of federal)		5.14			3.51
Warrant liability		(0.06	)		(0.30	)
Stock-based compensation		(2.68	)		(2.18	)
PPP Loan forgiveness		1.94			-
Other		(0.08	)		(0.05	)
Federal income tax provision effective rate		(0.39	)%		0.26	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	*December 31,*
	*2021*			*2020*
Deferred tax assets relating to:
Net operating loss carryforwards	$	60,977		$	59,050
Research and development tax carryforward		6,411			6,411
Stock-based compensation		4,807			4,219
Right-of-use liability		424			527
Property and equipment		14			18
Other deferred tax assets		288			343
Total gross deferred tax assets		72,921			70,568
Deferred tax liabilities relating to:
Right-of-use asset		(401	)		(464	)
Other deferred tax liabilities		(9	)		(12	)
Total gross deferred tax liabilities		(410	)		(476	)
Deferred tax assets less liabilities		72,511			70,092
Valuation allowance		(72,511	)		(70,092	)
Net deferred tax asset (liability)	$	-		$	-

Summary of Operating Loss Carryforwards [Table Text Block]

	*Net Operating*		*Research*
Year Incurred	*Loss CF*		*Activities Cr.*		*Expiration*
2007	$	454	$	30		2027
2008		1,178		65		2028
2009		3,060		176		2029
2010		3,423		149		2030
2011		9,929		176		2031
2012		-		170		2032
2013		4,353		133		2033
2014		15,897		894		2034
2015		23,496		598		2035
2016		41,580		745		2036
2017		34,776		652		2037
2018		56,099		2,271		Indefinite
2019		22,922		352		Indefinite
2020		8,784		-		Indefinite
2021		7,328		-		Indefinite
	$	233,279	$	6,411

Note H - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Loss Contingency Accrual, Ending Balance	$ 0	$ 0
Lessee, Lease, Option to Extend, Maximum Term (Year)	5 years
Lessee, Lease, Option to Terminate, Term (Year)	1 year
Operating and Capital Leases, Rent Expense, Net	$ 600	$ 600
IOWA
Lessee, Operating Lease, Renewal Term (Year)	1 year
FLORIDA
Lessee, Operating Lease, Renewal Term (Year)	5 years
Minimum [Member]
Lessee, Lease, Remaining Term of Contract (Year)	1 year
Capital Lease, Interest Rate	7.19%
Maximum [Member]
Lessee, Lease, Remaining Term of Contract (Year)	4 years
Capital Lease, Interest Rate	14.34%

Note J - Preferred Stock and Warrants - Preferred Stock Issued and Outstanding (Details) - shares	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Preferred Stock, Shares Authorized (in shares)	10,000,000		10,000,000
Preferred Stock, Shares Issued, Total (in shares)	0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)		9,578	9,578
Preferred Stock, Shares Issued, Total (in shares)			9,577
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			0
Series B-1 Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	0		1,576
Preferred Stock, Shares Issued, Total (in shares)	0	1,576	1,576
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0		0
Series B-2 Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	0		27,000
Preferred Stock, Shares Issued, Total (in shares)	0		27,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0		0

Note I - Supply Arrangement

12 Months Ended

Dec. 31, 2021

Collaborative Arrangement Disclosure [Text Block]

I.	Supply Arrangement

As of December 31, 2021, and 2020, the Company has one manufacturing arrangement that involves potential future expenditures related to research and development.

In November 2009, the Company entered into a supply agreement (the “Supply Agreement”) with Johnson Matthey Inc. (“JMI”) whereby JMI has agreed to supply the Company with all of the benzhydrocodone necessary for clinical trials and commercial sale for a price equal to JMI’s manufacturing cost and to provide process optimization and development services for benzhydrocodone. The Company’s FDA-approved drug, APADAZ, contains benzhydrocodone. The expense under this agreement for the year ended December 31, 2021, was negligible. The expense under this agreement for the year ended December 31, 2020, was $3.2 million. The Company must purchase all of its U.S. benzhydrocodone needs from JMI and JMI cannot supply benzhydrocodone to other companies. The term of the Supply Agreement extends as long as the Company holds a valid and enforceable patent for benzhydrocodone or until the tenth anniversary of a commercial launch of a FDA-approved drug incorporating benzhydrocodone, whichever date is later. Upon the expiration of such term, the agreement will automatically renew for a period of two years unless either party provides 12 months prior notice of its intent not to renew. Under the agreement, JMI will receive a tiered-based royalty share on the net sales on the commercial sale of a FDA-approved drug incorporating benzhydrocodone. No reliable estimate of the future payments can be made at this time.

Note N - Income Taxes (Details Textual) - USD ($)	12 Months Ended
Note N - Income Taxes (Details Textual) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
State and Local Income Tax Expense (Benefit), Continuing Operations, Total	$ 34,000	$ (34,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total	(8,521,000)	$ (12,794,000)
Operating Loss Carryforwards, Total	233,279,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	219,000,000.0
Operating Loss Carryforwards, Subject to Expiration	$ 142,400,000
Operating Loss Carryforwards, Expiration, Beginning Year	2027
Operating Loss Carryforwards, Not Subject to Expiration	$ 76,600,000

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 112,346	$ 4,213
Accounts and other receivables	1,528	2,579
Prepaid expenses and other current assets	1,182	1,481
Restricted cash	0	109
Total current assets	115,056	8,382
Property and equipment, net	884	1,039
Operating lease right-of-use assets	1,141	1,350
Long-term investments	15,422	0
Other long-term assets	438	438
Total assets	132,941	11,209
Liabilities and stockholders’ equity (deficit)
Accounts payable and accrued expenses	3,038	6,647
Current portion of operating lease liabilities	356	327
Current portion of loans payable	0	390
Other current liabilities	836	172
Total current liabilities	4,230	7,536
Convertible notes, less current portion, net	0	67,658
Derivative and warrant liability	330	304
Operating lease liabilities, less current portion	1,232	1,587
Loans payable, less current portion	0	391
Other long-term liabilities	31	145
Total liabilities	5,823	77,621
Commitments and contingencies (Note H)
Stockholders' equity (deficit):
Common stock	4	0
Additional paid-in capital	396,957	192,062
Treasury stock, at cost	(2,814)	0
Accumulated deficit	(267,029)	(258,474)
Total stockholders' equity (deficit)	127,118	(66,412)
Total liabilities and stockholders' equity (deficit)	132,941	11,209
Series A Convertible Preferred Stock [Member]
Stockholders' equity (deficit):
Preferred stock	0	0
Series B-1 Convertible Preferred Stock [Member]
Stockholders' equity (deficit):
Preferred stock	0	0
Series B-2 Convertible Preferred Stock [Member]
Stockholders' equity (deficit):
Preferred stock	0	0
Undesignated Preferred Stock [Member]
Stockholders' equity (deficit):
Preferred stock	$ 0	$ 0

Note R - Subsequent Events

12 Months Ended

Dec. 31, 2021

Subsequent Events [Text Block]

R.

Subsequent Events

On January 25, 2022, the Company filed an amendment to the registration statement on Form S-1 (File No. 333-250945) on Form S-3 covering the issuance of the shares of the Company's common stock issuable upon the exercise of the warrants issued in the Public Offering and remaining unexercised as of the date of the amendment, which was declared effective on February 1, 2022.

From January 1, 2022, through March 29, 2022, the Company repurchased 589,792 shares of its common stock for approximately $4.7 million under the Share Repurchase Program.

Note F - Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

	*December 31,*
	*2021*		*2020*
Accrued interest	$	-	$	1,158
Accrued banking fees		700		700
Accrued severance		-		53
Accrued payroll		1,054		1,299
Accrued professional fees		259		1,639
Accounts payable		516		1,174
Other accrued expenses		509		624
Total accounts payable and accrued expenses	$	3,038	$	6,647

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0
Preferred stock, shares outstanding (in shares)	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	35,325,801	4,537,321
Common stock, shares outstanding (in shares)	35,005,640	4,537,321
Series A Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	0	9,578
Preferred stock, shares issued (in shares)	0	9,577
Preferred stock, shares outstanding (in shares)	0	0
Series B-1 Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	0	1,576
Preferred stock, shares issued (in shares)	0	1,576
Preferred stock, shares outstanding (in shares)	0	0
Series B-2 Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	0	27,000
Preferred stock, shares issued (in shares)	0	27,000
Preferred stock, shares outstanding (in shares)	0	0
Undesignated Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	9,961,846
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Note H - Commitments and Contingencies - Maturities of lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
2022	$ 16
2022	463
2023	7
2023	472
2024	0
2024	484
2025	0
2025	390
2026	0
2026	30
Thereafter	0
Thereafter	0
Total lease payments	23
Total lease payments	1,839
Less: future interest expense	(2)
Less: future interest expense	(251)
Lease liabilities	21	$ 194
Lease liabilities	$ 1,588	$ 1,914

Note Q - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay		4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 164,000	$ 145,000
Profit Sharing Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0
Defined Contribution Plan, Requisite Service Period (Year)	3 years

Note N - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Net operating loss carryforwards	$ 60,977	$ 59,050
Research and development tax carryforward	6,411	6,411
Stock-based compensation	4,807	4,219
Right-of-use liability	424	527
Property and equipment	(14)	(18)
Other deferred tax assets	288	343
Total gross deferred tax assets	72,921	70,568
Right-of-use asset	(401)	(464)
Other deferred tax liabilities	(9)	(12)
Total gross deferred tax liabilities	(410)	(476)
Deferred tax assets less liabilities	72,511	70,092
Valuation allowance	(72,511)	(70,092)
Net deferred tax asset (liability)	$ 0	$ 0

Note K - Common Stock and Warrants - Common Stock Activity (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Balance (in shares)		4,537,321	2,271,882
Restricted stock vested during the period (in shares)			10,247
Common stock issued as compensation to third-parties (in shares)		35,129	23,216
Common stock issued as a result of stock option exercise (in shares)		0
Common stock issued as a result of warrant exercises (in shares)		18,772,510
Adjustment for cash paid in lieu of DTC fractional shares (in shares)		(1,356)
Common stock repurchased as a result of the Stock Repurchase Program		$ (320,161)
Conversion of Series B-2 Preferred Stock into Common Stock [Member]
Common stock issued as a result of Series B-2 Preferred Stock conversions (in shares)	4,842,699	4,842,699
Underwritten Public Offering [Member]
Common stock issued under equity line of credit (in shares)		7,139,498
2014 Equity Incentive Plan [Member]
Restricted stock vested during the period (in shares)		0	10,247
Common stock issued as a result of stock option exercise (in shares)		0	279
Optional Exchange Principal Amount [Member]
Common stock issued as a result of Deerfield Optional Conversion Feature conversion (in shares)			1,652,437
Equity Line of Credit [Member]
Common stock issued under equity line of credit (in shares)			579,260

Note L - Stock-based Compensation - Black-Scholes Option-pricing Model (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Risk-free interest rate	0.92%	0.38%
Expected term (in years) (Year)	5 years 6 months	5 years 6 months
Expected volatility	96.91%	89.49%
Maximum [Member]
Risk-free interest rate	1.55%	1.65%
Expected term (in years) (Year)	10 years	10 years
Expected volatility	102.57%	93.07%

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 28,650	$ 13,288
Operating expenses:
Royalty and direct contract acquisition costs	2,059	1,305
Research and development	10,161	8,843
General and administrative	8,701	7,921
Severance expense	0	828
Total operating expenses	20,921	18,897
Income (loss) from operations	7,729	(5,609)
Other (expense) income:
Loss on extinguishment of debt	(16,096)	0
Interest expense related to amortization of debt issuance costs and discount	(150)	(2,305)
Interest expense on principal	(226)	(4,785)
Fair value adjustment related to derivative and warrant liability	(26)	(184)
Interest and other income, net	248	89
Total other (expense) income	(16,250)	(7,185)
Loss before income taxes	(8,521)	(12,794)
Income tax (expense) benefit	(34)	34
Net income (loss)	(8,555)	(12,760)
Deemed dividend	(54,342)	0
Net loss attributable to common stockholders	$ (62,897)	$ (12,760)
Basic net loss per share of common stock:
Net loss attributable to common stockholders (in dollars per share)	$ (2.11)	$ (3.21)
Diluted net loss per share of common stock:
Net loss attributable to common stockholders (in dollars per share)	$ (2.11)	$ (3.21)
Weighted average number of shares of common stock outstanding:
Basic (in shares)	29,766,347	3,980,975
Diluted (in shares)	29,766,347	3,980,975

Note M - Fair Value of Financial Instruments (Details Textual)	12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Deerfield Warrant Liability [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 288,000	$ 230,000
Liabilities, Fair Value Disclosure, Increase from Ten Percent Increase in Enterprise Value	50,000
Liabilities, Fair Value Disclosure, Estimated Amount of Weighted-average Probability of Liquidity Event	55,000,000.0
Liabilities, Fair Value Disclosure, Estimated Amount of Weighted-average Probability of Fundamental Change	$ 680,000,000
Deerfield Warrant Liability [Member] \| Weighted Average Probability of Liquidity Event [Member]
Derivative Liability, Measurement Input	0.23
Deerfield Warrant Liability [Member] \| Weighted Average Probability of Fundamental Change [Member]
Derivative Liability, Measurement Input	0.34
Embedded Put Option [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 18,000	25,000
Liabilities, Fair Value Disclosure, Increase from Ten Percent Increase in Enterprise Value	3,000
Fair Value, Inputs, Level 3 [Member] \| The 2019 Notes [Member]
Long-term Debt, Fair Value		56,200,000
Fair Value, Inputs, Level 3 [Member] \| January 2020 Note [Member]
Long-term Debt, Fair Value	$ 0	3,100,000
Fair Value, Inputs, Level 3 [Member] \| Deerfield Facility Agreement [Member] \| Deerfield Convertible Notes [Member]
Long-term Debt, Fair Value		$ 7,300,000

Note O - Net Loss Per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Text Block]

O.	Net Loss Per Share

Under the two-class method, for periods with net income, basic net income per share of common stock is computed by dividing the net income attributable to shares of common stock by the weighted average number of shares of common stock outstanding during the period. Net income attributable to shares of common stock is computed by subtracting from net income the portion of current period earnings that participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss as the holders of the participating securities have no obligation to fund losses. Diluted net income (loss) per share of common stock is computed under the two-class method by using the weighted average number of shares of common stock outstanding plus the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding convertible securities under the if-converted method when calculating diluted income (loss) per share of common stock in which it is assumed that the outstanding convertible securities convert into common stock at the beginning of the period or date of issuance, if the convertible security was issued during the period. The Company reports the more dilutive of the approaches (two-class or if-converted) as its diluted net income (loss) per share of common stock during the period.

The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average number of shares of common stock outstanding because their effect is anti-dilutive:

	*December 31,*
	*2021*		*2020*
Conversion of Deerfield Convertible Note		-		81,101
Conversion of January 2020 Note		-		34,615
Conversion of December 2019 Notes		-		625,747
Outstanding awards under equity incentive plans		1,273,879		355,785
Outstanding common stock warrants		4,221,350		151,442
Total securities excluded from the calculation of weighted average number of shares of common stock outstanding		5,495,229		1,248,690

A reconciliation from net loss to basic net loss attributable to common stockholders per share of common stock and diluted net loss attributable to common stockholders per share of common stock for the years ended December 31, 2021, and 2020, is as follows (in thousands):

	December 31,
	2021			2020
Basic net loss per share of common stock:

Net loss	$	(8,555	)	$	(12,760	)
Less: Dividends declared or accumulated		(54,342	)		-
Net loss attributable to common stockholders	$	(62,897	)	$	(12,760	)
Less: Net loss attributable to participating securities		-			-
Undistributed net loss attributable to shares of common stockholders, basic	$	(62,897	)	$	(12,760	)
Weighted average number of shares of common stock outstanding, basic		29,766			3,981
Basic net loss attributable to common stockholders per share of common stock	$	(2.11	)	$	(3.21	)

Diluted net loss per share of common stock:

Undistributed net loss attributable to common stockholders	$	(62,897	)	$	(12,760	)
Less: Fair value adjustment income related to KVK Warrant liability		(26	)		-
Undistributed net loss attributable to common stockholders, diluted	$	(62,923	)	$	(12,760	)
Weighted average number of shares of common stock outstanding, basic		29,766			3,981
Dilutive effect of KVK Warrant		0			-
Weighted-average number of shares of common stock outstanding, diluted		29,766			3,981
Diluted loss attributable to common stockholders per share of common stock	$	(2.11	)	$	(3.21	)

Note H - Commitments and Contingencies - Supplement Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating cash flows from finance leases	$ 9	$ 23
Financing cash flows from finance leases	173	227
Operating cash flows from operating leases	460	447
Operating cash flows from short-term leases	199	210
Operating cash flows from variable lease costs	47	55
Finance leases	0	17
Operating leases	$ 0	$ 20

Note E - Property and Equipment - Components of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property and equipment, gross	$ 2,809	$ 2,765
Less: accumulated depreciation and amortization	(1,925)	(1,726)
Property and equipment, net	884	1,039
Laboratory Equipment [Member]
Property and equipment, gross	645	643
Furniture and Fixtures [Member]
Property and equipment, gross	71	71
Computer and Hardware [Member]
Property and equipment, gross	338	296
Leasehold Improvements [Member]
Property and equipment, gross	724	724
Finance Lease, Right-of-Use Assets [Member]
Property and equipment, gross	$ 1,031	$ 1,031

Note E - Property and Equipment

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment Disclosure [Text Block]

E.	Property and Equipment

Property and equipment consists of the following (in thousands):

	*December 31,*
	*2021*			*2020*
Laboratory equipment	$	645		$	643
Furniture and office equipment		71			71
Computers and hardware		338			296
Leasehold improvements		724			724
Finance lease right-of-use assets		1,031			1,031
Total property and equipment		2,809			2,765
Less: accumulated depreciation and amortization		(1,925	)		(1,726	)
Property and equipment, net	$	884		$	1,039

The estimated useful lives of property and equipment are as follows:

		*Useful Life*
Asset Category		*(in years)*
Laboratory equipment		10
Furniture and office equipment		5 - 10
Computers and hardware		3 - 7
Leasehold improvements		9

Depreciation and amortization expense, including amounts pertaining to assets held under finance leases, was approximately $257,000 and $273,000 for the years ended December 31, 2021, and 2020, respectively.

Note J - Preferred Stock and Warrants - Preferred Stock Issued and Outstanding (Details) (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)		$ 0.0001
Series B-1 Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	0.0001
Series B-2 Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001

Note L - Stock-based Compensation (Details Textual) - USD ($)		1 Months Ended	12 Months Ended
	Jan. 01, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 30, 2021	Dec. 31, 2020
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)					10,247
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)			0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)			$ 7.53		$ 5.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 2,000,000.0		$ 3,700,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 5,800,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			3 years 2 months 1 day
Share-based Payment Arrangement, Expense				$ 2,436,000	2,491,000
Performance Shares [Member]
Share-based Payment Arrangement, Expense			$ 400,000		$ 300,000
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		4,900,000,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			5,489,660
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding		4.00%
Increase in Common Stock Reserved for Issuance (in shares)	1,400,225
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)			0		10,247
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)			0		279
Stock Issued During Period, Value, Stock Options Exercised					$ 2,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value					$ 1,000

Note K - Common Stock and Warrants

12 Months Ended

Dec. 31, 2021

Stockholders' Equity Note Disclosure [Text Block]

K.	Common Stock and Warrants

Authorized, Issued, and Outstanding Common Shares

As of December 31, 2021, and 2020, the Company had authorized shares of common stock of 250,000,000 shares. Of the authorized shares, 35,325,801 and 4,537,321 shares of common stock were issued as of December 31, 2021, and 2020, respectively, and 35,005,640 and 4,537,321 shares of common stock were outstanding as of December 31, 2021, and 2020, respectively.

As of December 31, 2021, and 2020, the Company had reserved authorized shares of common stock for future issuance as follows:

	*December 31,*
	*2021*		*2020*
Conversion of Deerfield Convertible Note		-		81,101
Conversion of January 2020 Note		-		34,615
Conversion of December 2019 Notes		-		625,747
Outstanding awards under equity incentive plans		1,273,879		355,785
Outstanding common stock warrants		4,252,600		151,442
Possible future issuances under equity incentive plans		4,209,935		-
Possible future issuances under employee stock purchase plan		1,500,000		47,825
Total common shares reserved for future issuance		11,236,414		1,296,515

Common Stock Activity

The following table summarizes common stock activity for the years ended December 31, 2021, and 2020:

	*Shares of*
	*Common Stock*
Balance as of January 1, 2020		2,271,882
Common stock issued under equity line of credit		579,260
Restricted stock vested during the period		10,247
Common stock issued as compensation to third-parties		23,216
Common stock issued as a result of Deerfield Optional Conversion Feature conversion		1,652,437
Common stock issued as a result of stock option exercise		279
Balance as of December 31, 2020		4,537,321
Common stock issued as a result of the Public Offering		7,139,498
Common stock issued as a result of Series B-2 Preferred Stock conversions		4,842,699
Common stock issued as a result of warrant exercises		18,772,510
Common stock issued as compensation to third-parties		35,129
Adjustment for cash paid in lieu of DTC fractional shares		(1,356	)
Common stock repurchased as a result of the Stock Repurchase Program		(320,161	)
Balance as of December 31, 2021		35,005,640

Warrants

On June 2, 2014, pursuant to the terms of the Deerfield Facility Agreement, the Company issued the Deerfield Warrant to purchase 14,423,076 shares of Series D Preferred (Note C). The Company recorded the fair value of the Deerfield Warrant as a debt discount and a warrant liability. The Deerfield Warrant, if unexercised, expires on the earlier of June 2, 2024, or upon a liquidation event. Upon completion of the Company’s initial public offering (the “IPO”), the Deerfield Warrant automatically converted into a warrant to purchase 1,923,077 shares of the Company’s common stock at an exercise price of $5.85 per share. After giving effect to the Reverse Stock Split effected in December 2020, the exercise price of the Deerfield Warrant became $93.60 and the shares of the Company’s common stock issuable upon exercise of the Deerfield Warrant became 120,192 shares of common stock. As a result of the January 2021 Inducement Transaction (discussed below) the anti-dilution provisions within the Deerfield Warrant were triggered and the exercise price was reduced from $93.60 per share to $46.25 per share. In addition, as a result of the June 2021 Inducement Transaction (discussed below) the anti-dilution provision within the Deerfield Warrant were triggered and the exercise price was reduced from $46.25 per share to $38.34 per share. The Company amortized the debt discount over the term of the Deerfield Convertible Note and the expense was recorded as interest expense related to amortization of debt issuance costs and discount in the statements of operations. The Deerfield Convertible Note was extinguished in February 2021 and the remaining debt discount was written off and recognized as a loss on extinguishment of debt.

The Company determined that the Deerfield Warrant should be recorded as a liability and stated at fair value at each reporting period upon inception. As stated above, upon completion of the IPO, the Deerfield Warrant automatically converted into warrants to purchase the Company’s common stock. The Deerfield Warrant remains classified as a liability and is recorded at fair value at each reporting period since it can be settled in cash. Changes to the fair value of the warrant liability are recorded through the statements of operations as a fair value adjustment (Note M).

In connection with the APADAZ License Agreement, in October 2018, the Company issued to KVK a warrant to purchase up to 500,000 shares of common stock of the Company at an exercise price of $2.30 per share, which reflected the closing price of the Company’s common stock on the Nasdaq Stock Market on the execution date of the APADAZ License Agreement (the “KVK Warrant”). The KVK Warrant is initially not exercisable for any shares of common stock. Upon the achievement of each of four specified milestones under the KVK Warrant, the KVK Warrant will become exercisable for an additional 125,000 shares, up to an aggregate of 500,000 shares of the Company’s common stock. The exercise price and the number and type of shares underlying the KVK Warrant are subject to adjustment in the event of specified events, including a reclassification of the Company’s common stock, a subdivision or combination of the Company’s common stock, or in the event of specified dividend payments. The KVK Warrant is exercisable until October 24, 2023. Upon exercise, the aggregate exercise price may be paid, at KVK’s election, in cash or on a net issuance basis, based upon the fair market value of the Company’s common stock at the time of exercise. After giving effect to the Reverse Stock Split effected in December 2020, the exercise price of the KVK Warrant became $36.80 and the shares of common stock issuable upon exercise of the KVK Warrant became 31,250 shares of common stock.

The Company determined that, since KVK qualifies as a customer under ASC 606, the KVK Warrant should be recorded as a contract asset and recognized as contra-revenue as the Company recognizes revenue from the APADAZ License Agreement. In addition, the Company determined that the KVK Warrant qualifies as a derivative under ASC 815 and should be recorded as a liability and stated at fair value each reporting period. The Company calculates the fair value of the KVK Warrant using a probability-weighted Black-Scholes option pricing model. Changes in fair value resulting from changes in the inputs to the Black Scholes model are accounted for as changes in the fair value of the derivative under ASC 815 and are recorded as fair value adjustment related to derivative and warrant liability in the statements of operations. Changes in the number of shares that are expected to be issued are treated as changes in variable consideration under ASC 606 and are recorded as a change in contract asset on the balance sheets. As of December 31, 2021, and 2020, a contract asset of $0.4 million is recorded in other long-term assets on the balance sheets related to the KVK Warrant.

Pre-Funded Warrants

On January 12, 2021, pursuant to the terms of the Underwriting Agreement, the Company issued pre-funded warrants to purchase 926,844 shares of the Company’s common stock to specified investors in the Public Offering. Each pre-funded warrant had an initial exercise price per share equal to $0.0001. The pre-funded warrants were immediately exercisable. The pre-funded warrants were exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise notice accompanied by payment in full for the number of shares of common stock purchased upon such exercise. In lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder was able to elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrants. In January 2021, all pre-funded warrants were exercised for 926,841 shares of common stock and gross proceeds of approximately $72.

Warrants to Purchase Common Stock

On January 12, 2021, pursuant to the terms of the Underwriting Agreement and December 2020 Exchange Agreement, the Company issued warrants to purchase 12,078,361 shares of the Company’s common stock (collectively, the “Offering Warrants”) in the Public Offering and in connection with the transactions contemplated under the December 2020 Exchange Agreement. The Offering Warrants were immediately exercisable and expire on the fifth anniversary of their issuance date, at an exercise price per share of common stock equal to $6.50 per share. The Offering Warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise notice, provided that payment in full for the number of shares of the Company’s common stock purchased upon such exercise is delivered to the Company in accordance with the terms of the Offering Warrants. In lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Offering Warrants. A holder (together with its affiliates) may not exercise any portion of the Offering Warrant to the extent that the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would own more than 4.99% of the Company’s outstanding common stock immediately after exercise. Except as otherwise provided in the Offering Warrants or by virtue of such holder’s ownership of shares of the Company’s common stock, the holders of the Offering Warrants do not have the rights or privileges of holders of common stock with respect to the shares of common stock underlying the Offering Warrants, including any voting rights, until they exercise their Offering Warrants. The Offering Warrants provide that holders have the right to participate in distributions or dividends paid on the Company’s common stock. In the event of a fundamental transaction, as described in the Offering Warrants and generally including any reorganization, recapitalization or reclassification of the Company’s common stock, the sale, transfer or other disposition of all or substantially all of the Company’s properties or assets, the Company’s consolidation or merger with or into another person, the acquisition of more than 50% of the Company’s outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by the Company’s outstanding common stock, the holders of the Offering Warrants will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Offering Warrants immediately prior to such fundamental transaction. In addition, in the event of a fundamental transaction which is approved by the Company’s board of directors, the holders of the warrants have the right to require the Company or a successor entity to redeem the Offering Warrants for cash in the amount of the Black Scholes value of the unexercised portion of the Offering Warrants on the date of the consummation of the fundamental transaction. In the event of a fundamental transaction which is not approved by the Company’s board of directors, the holders of the Offering Warrants have the right to require the Company or a successor entity to redeem the Offering Warrants in the amount of the Black Scholes value of the unexercised portion of the Offering Warrants on the date of the consummation of the fundamental transaction payable in the form of consideration paid to the holders of common stock in such fundamental transaction. The Offering Warrants meet the equity classification requirements and thus are recorded in additional paid-in capital on the unaudited condensed balance sheets. As of December 31, 2021, 3,461,858 Offering Warrants have been exercised for 3,030,881 shares of common stock and gross proceeds of approximately $16.9 million. These amounts are exclusive of the Offering Warrants exercised as part of the January 2021 Inducement Transaction discussed below.

Underwriter Warrant

On January 12, 2021, pursuant to the terms of the Underwriting Agreement, the Company issued to the Underwriter a warrant to purchase 806,932 shares of the Company’s common stock (the “Underwriter Warrant”). The Underwriter Warrant is subject to substantially the same terms and conditions as the Warrants, provided that the exercise price for the Underwriter Warrant is $8.125 per share. If the Underwriter exercises any additional portion of its over-allotment option, then the Company shall issue the Underwriter an additional Underwriter Warrant exercisable for a number of shares of common stock equal to 5.0% of the number of shares of common stock issued in such over-allotment exercise (including the shares of common stock issuable upon the exercise of any Warrants issued in connection therewith). In connection with the closing of the Underwriter's partial exercise of its over-allotment option, on February 3, 2021, the Underwriter was issued an additional warrant to purchase 18,702 shares of common stock. As of December 31, 2021, 400,000 Underwriter Warrants have been exercised for 400,000 shares of common stock and gross proceeds of approximately $3.3 million.

January 2021 Warrant Exercise Inducement Letters and Issuance of Warrants

On January 26, 2021, the Company entered into warrant exercise inducement offer letters ( “January 2021 Inducement Transaction”) with certain holders of warrants issued in the Public Offering discussed above (the "Existing Warrants") (collectively, the “Exercising Holders”) pursuant to which such holders agreed to exercise for cash their Existing Warrants to purchase 6,620,358 shares of the Company’s common stock in exchange for the Company’s agreement to issue new warrants (the “January 2021 Inducement Warrants”) on substantially the same terms as the Existing Warrants, except as set forth in the following sentence, to purchase up to 7,944,430 shares of the Company’s common stock, which is equal to 120% of the number of shares of the Company’s common stock issued upon exercise of the Existing Warrants. The purchase price of the January 2021 Inducement Warrants was $0.125 per share underlying each January 2021 Inducement Warrant, and the January 2021 Inducement Warrants have an exercise price of $6.36 per share. The Company received aggregate gross proceeds of approximately $44.0 million from the exercise of the Existing Warrants by the Exercising Holders and the sale of the January 2021 Inducement Warrants. The Company engaged Roth as its exclusive placement agent in connection with these transactions and paid Roth a fee equal to 6% of gross proceeds from the exercise of the Existing Warrants by the Exercising Holders and the sale of the January 2021 Inducement Warrants. As a result of this transaction the anti-dilution provisions contained with the Deerfield Warrant were triggered and the exercise price of the Deerfield Warrant was reduced from $93.60 per share to $46.25 per share.

The January 2021 Inducement Warrants were immediately exercisable and expire on the fifth anniversary of their issuance date, at an exercise price per share of common stock equal to $6.36 per share. The January 2021 Inducement Warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise notice, provided that payment in full for the number of shares of the Company’s common stock purchased upon such exercise is delivered to the Company in accordance with the terms of the January 2021 Inducement Warrants. In lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the warrants. A holder (together with its affiliates) may not exercise any portion of the January 2021 Inducement Warrant to the extent that the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would own more than 4.99% (or, upon election by a holder prior to the issuance of its January 2021 Inducement Warrants, 9.99%) of the Company’s outstanding common stock immediately after exercise. Except as otherwise provided in the January 2021 Inducement Warrants or by virtue of such holder’s ownership of shares of the Company’s common stock, the holders of the January 2021 Inducement Warrants do not have the rights or privileges of holders of common stock with respect to the shares of common stock underlying the January 2021 Inducement Warrants, including any voting rights, until they exercise their January 2021 Inducement Warrants. The January 2021 Inducement Warrants provide that holders have the right to participate in distributions or dividends paid on the Company’s common stock. In the event of a fundamental transaction, as described in the January 2021 Inducement Warrants and generally including any reorganization, recapitalization or reclassification of the Company’s common stock, the sale, transfer or other disposition of all or substantially all of the Company’s properties or assets, the Company’s consolidation or merger with or into another person, the acquisition of more than 50% of the Company’s outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by the Company’s outstanding common stock, the holders of the January 2021 Inducement Warrants will be entitled to receive upon exercise of the January 2021 Inducement Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the January 2021 Inducement Warrants immediately prior to such fundamental transaction. In addition, in the event of a fundamental transaction which is approved by the Company’s board of directors, the holders of the January 2021 Inducement Warrants have the right to require the Company or a successor entity to redeem the January 2021 Inducement Warrants for cash in the amount of the Black Scholes value of the unexercised portion of the January 2021 Inducement Warrants on the date of the consummation of the fundamental transaction. In the event of a fundamental transaction which is not approved by the Company’s board of directors, the holders of the January 2021 Inducement Warrants have the right to require the Company or a successor entity to redeem the January 2021 Inducement Warrants in the amount of the Black Scholes value of the unexercised portion of the January 2021 Inducement Warrants on the date of the consummation of the fundamental transaction payable in the form of consideration paid to the holders of common stock in such fundamental transaction. As of December 31, 2021, 1,676,921 January 2021 Inducement Warrants have been exercised for 1,676,921 shares of common stock and gross proceeds of approximately $10.7 million. These amounts are exclusive of the January 2021 Inducement Warrants exercised as part of the June 2021 Inducement Transaction discussed below.

In accordance with the January 2021 Inducement Transaction we recognized a deemed dividend of $37.4 million which is the difference between the grant date fair value of the January 2021 Inducement Warrants and the purchase price of the January 2021 Inducement Warrants. This deemed dividend is added to net loss to arrive at net loss attributable to common stockholders on the statements of operations.

June 2021 Warrant Exercise Inducement Letters and Issuance of Warrants

On June 18, 2021, the Company entered into warrant exercise inducement offer letters ( “June 2021 Inducement Transaction”) with certain holders of warrants issued in the January 2021 Inducement Transaction discussed above (the "January 2021 Inducement Warrants") (collectively, the “June 2021 Exercising Holders”) pursuant to which such holders agreed to exercise for cash their January 2021 Inducement Warrants to purchase 6,117,509 shares of the Company’s common stock in exchange for the Company’s agreement to issue new warrants (the “June 2021 Inducement Warrants”) on substantially the same terms as the January 2021 Inducement Warrants, except as set forth in the following sentence, to purchase up to 1,529,379 shares of the Company’s common stock, which is equal to 25% of the number of shares of the Company’s common stock issued upon exercise of the January 2021 Inducement Warrants. The purchase price of the June 2021 Inducement Warrants was $0.125 per share underlying each June 2021 Inducement Warrant, and the June 2021 Inducement Warrants have an exercise price of $16.50 per share. The Company received aggregate gross proceeds of approximately $39.1 million from the exercise of the January 2021 Inducement Warrants by the June 2021 Exercising Holders and the sale of the June 2021 Inducement Warrants. The Company engaged Roth as its exclusive placement agent in connection with these transactions and paid Roth a fee equal to 6% of gross proceeds from the exercise of the January 2021 Inducement Warrants by the June 2021 Exercising Holders and the sale of the June 2021 Inducement Warrants. As a result of this transaction the anti-dilution provisions contained with the Deerfield Warrant were triggered and the exercise price of the Deerfield Warrant was reduced from $46.25 per share to $38.34 per share.

The June 2021 Inducement Warrants were immediately exercisable and expire on December 31, 2026, at an exercise price per share of common stock equal to $16.50 per share. The June 2021 Inducement Warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise notice, provided that payment in full for the number of shares of the Company’s common stock purchased upon such exercise is delivered to the Company in accordance with the terms of the June 2021 Inducement Warrants. In lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the warrants. A holder (together with its affiliates) may not exercise any portion of the June 2021 Inducement Warrant to the extent that the holder and its affiliates and any other person or entities with which such holder would constitute a Section 13(d) “group” would own more than 4.99% (or, upon election by a holder prior to the issuance of its June 2021 Inducement Warrants, 9.99%) of the Company’s outstanding common stock immediately after exercise. Except as otherwise provided in the June 2021 Inducement Warrants or by virtue of such holder’s ownership of shares of the Company’s common stock, the holders of the June 2021 Inducement Warrants do not have the rights or privileges of holders of common stock with respect to the shares of common stock underlying the June 2021 Inducement Warrants, including any voting rights, until they exercise their June 2021 Inducement Warrants. The June 2021 Inducement Warrants provide that holders have the right to participate in distributions or dividends paid on the Company’s common stock. In the event of a fundamental transaction, as described in the June 2021 Inducement Warrants and generally including any reorganization, recapitalization or reclassification of the Company’s common stock, the sale, transfer or other disposition of all or substantially all of the Company’s properties or assets, the Company’s consolidation or merger with or into another person, the acquisition of more than 50% of the Company’s outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by the Company’s outstanding common stock, the holders of the June 2021 Inducement Warrants will be entitled to receive upon exercise of the June 2021 Inducement Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the June 2021 Inducement Warrants immediately prior to such fundamental transaction. In addition, in the event of a fundamental transaction which is approved by the Company’s board of directors, the holders of the June 2021 Inducement Warrants have the right to require the Company or a successor entity to redeem the June 2021 Inducement Warrants for cash in the amount of the Black Scholes value of the unexercised portion of the June 2021 Inducement Warrants on the date of the consummation of the fundamental transaction. In the event of a fundamental transaction which is not approved by the Company’s board of directors, the holders of the June 2021 Inducement Warrants have the right to require the Company or a successor entity to redeem the June 2021 Inducement Warrants in the amount of the Black Scholes value of the unexercised portion of the June 2021 Inducement Warrants on the date of the consummation of the fundamental transaction payable in the form of consideration paid to the holders of common stock in such fundamental transaction. As of December 31, 2021, no June 2021 Inducement Warrants have been exercised.

In accordance with the June 2021 Inducement Transaction we recognized a deemed dividend of $16.9 million which is the difference between the grant date fair value of the June 2021 Inducement Warrants and the purchase price of the June 2021 Inducement Warrants. This deemed dividend is added to net loss to arrive at net loss attributable to common stockholders on the statements of operations.

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Note O - Net Loss Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net loss	$ (8,555)	$ (12,760)
Less: Dividends declared or accumulated	(54,342)	0
Net (loss) income attributable to common stockholders	(62,897)	(12,760)
Less: Net income attributable to participating securities	0	0
Undistributed net (loss) income attributable to common stockholders, basic	$ (62,897)	$ (12,760)
Weighted average number of shares of common stock outstanding, basic (in shares)	29,766,347	3,980,975
Basic net (loss) income attributable to common stockholders per share of common stock (in dollars per share)	$ (2.11)	$ (3.21)
Undistributed net loss attributable to common stockholders, diluted	$ (62,923)	$ (12,760)
Weighted-average number of shares of common stock outstanding, diluted (in shares)	29,766,347	3,980,975
Diluted loss attributable to common stockholders per share of common stock (in dollars per share)	$ (2.11)	$ (3.21)
Warrant [Member] \| KVK Warrant [Member]
Less: Fair value adjustment income related to warrant liability	$ (26)	$ 0
Dilutive effect of warrant (in shares)	0	0

Note G - Debt Obligations (Details Textual) - USD ($)									1 Months Ended	9 Months Ended	12 Months Ended
Note G - Debt Obligations (Details Textual) - USD ($)	Feb. 08, 2021	Jan. 12, 2021	Jan. 01, 2021	Apr. 23, 2020	Jan. 13, 2020	Dec. 18, 2019	Feb. 09, 2016	Jun. 02, 2014	Jun. 30, 2018	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 18, 2021	Mar. 31, 2021	Jan. 26, 2021	Dec. 31, 2019	Sep. 30, 2019	Sep. 02, 2019	Jun. 30, 2016
Convertible Notes Payable, Total											$ 0	$ 68,200,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)										1,777,437
Interest Paid, Excluding Capitalized Interest, Operating Activities											218,000	78,000
Debt Instrument, Convertible, Minimum Conversion Price (in dollars per share)																$ 9.328
Proceeds from Issuance of Long-term Debt, Total											$ 0	$ 781,000
Conversion from Deerfield Convertible Note to Common Stock [Member]
Debt Conversion, Original Debt, Amount									$ 3,300,000
Debt Conversion, Accrued Interest									$ 200,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)									37,410
Conversion of December 2019 Notes into Common Stock [Member]
Debt Conversion, Original Debt, Amount										$ 17,100,000
December 2020 Exchange Agreement [Member]
Debt Conversion, Original Debt, Amount		$ 31,500,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)		31,476.98412
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)		3,632,019
Deerfield Convertible Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)																93.60
2021 Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)							$ 17.11					$ 273.76
Debt Conversion, Original Debt, Amount							$ 1,000					$ 1,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)							58.4454					3.6528
Debt Instrument, Interest Rate, Stated Percentage							5.50%
Debt Instrument, Face Amount							$ 86,300,000
Proceeds from Debt, Net of Issuance Costs							82,800,000
Repayments of Long-term Debt, Total							18,600,000
Debt Instrument, Sinking Fund Payment							$ 0
Debt Instrument Repurchase Price Equal to Percentage of Principal Amount							100.00%
Debt Instrument, Cancellation of Debt, Amount					$ 3,000,000.0	$ 71,400,000
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 37,000	$ 700,000
Debt Instrument, Percentage of Accrued Interest Paid						50.00%
The 2019 Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 5.85	$ 17.11						$ 93.60				273.76
Debt Instrument, Interest Rate, Stated Percentage						6.75%
Debt Instrument, Face Amount						$ 71,400,000
Debt Instrument, Percentage of Accrued Interest Paid					50.00%
Debt Instrument, Convertible, Minimum Conversion Price (in dollars per share)					$ 0.583											$ 0.38
Debt Instrument, Convertible, Conversion Restriction Percentage of Common Stock						4.985%
Beneficial Ownership, Cap Limit, Percentage						19.985%
Debt Instrument, Convertible, Floor Price (in dollars per share)												$ 9.328
January 2020 Note [Member]
Debt Instrument, Face Amount					$ 3,000,000.0
The December 2020 Exchange Agreement [Member]
Repayments of Debt			$ 30,300,000
The December 2019 and January 2020 Notes [Member]
Long-term Debt, Gross												$ 60,800,000
Deerfield Facility Agreement [Member]
Long-term Debt, Gross												7,500,000
The Facility Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		6.75%
Repayments of Long-term Debt, Total		$ 30,300,000
Long-term Debt, Total		$ 7,600,000										$ 69,400,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total				$ 800,000
Deerfield Facility Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 60,000,000
Line of Credit Facility, Interest Rate at Period End								9.75%											6.75%
Debt Instrument, Interest Rate, Stated Percentage																	6.75%	9.75%
Convertible Notes Payable, Current														$ 7,000,000.0
Debt Covenant, Debt Financing Restriction								$ 750,000
Repayments of Long-term Debt, Total	$ 8,000,000.0
Debt Instrument, Convertible, Minimum Conversion Price (in dollars per share)						$ 0.60
Conversion of Stock, Maximum Shares Issued (in shares)						28,439,015
Debt Instrument, Convertible, Optional Conversion Feature, Exchange Price (in dollars per share)												$ 9.60
Debt Instrument, Convertible Optional Conversion Feature Shares Issuable Upon Exchange (in shares)												1,777,437
Deerfield Facility Agreement [Member] \| Deerfield Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 0.78
Deerfield Facility Agreement [Member] \| Deerfield Warrant [Member] \| IPO [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,923,077
Deerfield Facility Agreement [Member] \| Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								14,423,076
Deerfield Facility Agreement [Member] \| Term Notes [Member]
Proceeds from Secured Notes Payable								$ 15,000,000
Deerfield Facility Agreement [Member] \| Deerfield Convertible Notes [Member]
Proceeds from Secured Notes Payable								$ 10,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)								$ 5.85				$ 93.60
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												120,192
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 5.85				$ 93.60	$ 38.34		$ 46.25

Note K - Common Stock and Warrants (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block]

	*December 31,*
	*2021*		*2020*
Conversion of Deerfield Convertible Note		-		81,101
Conversion of January 2020 Note		-		34,615
Conversion of December 2019 Notes		-		625,747
Outstanding awards under equity incentive plans		1,273,879		355,785
Outstanding common stock warrants		4,252,600		151,442
Possible future issuances under equity incentive plans		4,209,935		-
Possible future issuances under employee stock purchase plan		1,500,000		47,825
Total common shares reserved for future issuance		11,236,414		1,296,515

Schedule of Common Stock Outstanding Roll Forward [Table Text Block]

	*Shares of*
	*Common Stock*
Balance as of January 1, 2020		2,271,882
Common stock issued under equity line of credit		579,260
Restricted stock vested during the period		10,247
Common stock issued as compensation to third-parties		23,216
Common stock issued as a result of Deerfield Optional Conversion Feature conversion		1,652,437
Common stock issued as a result of stock option exercise		279
Balance as of December 31, 2020		4,537,321
Common stock issued as a result of the Public Offering		7,139,498
Common stock issued as a result of Series B-2 Preferred Stock conversions		4,842,699
Common stock issued as a result of warrant exercises		18,772,510
Common stock issued as compensation to third-parties		35,129
Adjustment for cash paid in lieu of DTC fractional shares		(1,356	)
Common stock repurchased as a result of the Stock Repurchase Program		(320,161	)
Balance as of December 31, 2021		35,005,640

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases, and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of long-term investments and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit and investments with multiple financial institutions, the balances of which frequently exceed insured limits, and accounts receivable, which are concentrated amongst a limited number of customers.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash equivalents.

Investment, Policy [Policy Text Block]

Long-term Investments

The Company maintains investment securities that are classified as trading securities. These securities are carried at fair value with unrealized gains and losses included in other (expense) income on the statements of operations. The securities primarily consist of certificates of deposit, U.S. Treasury securities and U.S. government-sponsored agency securities. As of December 31, 2021, the Company held long-term investments with an aggregate fair value of $15.4 million that contained aggregate unrealized losses of $13,000. These long-term investments have been in a continuous unrealized loss position for less than 12 months and the Company expects these investments to fully recover prior to their maturity. The unrealized losses are primarily driven by interest rate changes and are not credit related. The Company had no long-term investments as of December 31, 2020.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to ten years. Leasehold improvements are amortized over the shorter of the useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in the statements of operations.

Debt, Policy [Policy Text Block]

Debt Issuance Costs

Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method.

Deferred Charges, Policy [Policy Text Block]

Offering Costs

Offering costs incurred in connection with capital offering arrangements are recorded as deferred offering costs in prepaid expenses and other currents assets on the balance sheet. Once the offering arrangement closes the deferred offering costs are reclassified as a reduction of the related net proceeds of the offering in additional paid-in capital on the balance sheet. If it's a continuous offering the deferred offering costs are amortized over the life of the respective offering arrangement using a pro-rata method which matches the costs to the funds raised from the offering. If the continuous offering arrangement terminates prior to all the deferred offering costs being recognized the deferred offering costs are written off and expensed in general and administrative expense on the statement of operations.

Collaborative Arrangement, Accounting Policy [Policy Text Block]

Supply Arrangements

The Company enters into supply arrangements for the supply of components of its products and product candidates. These arrangements also may include a share of future revenue if related products or product candidates reach commercialization. Costs under these supply arrangements, if any, are expensed as incurred (Note I).

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying values, an impairment loss is recorded for the difference between the carrying values and fair values of the asset. No such impairment occurred for the years ended December 31, 2021, or 2020 .

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

●

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

●

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

●

Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

The Company commenced recognizing revenue in accordance with the provisions of ASC 606, Revenue from Contracts with Customers (“ASC 606”), starting January 1, 2018.

Arrangements with Multiple-Performance Obligations

From time to time, the Company enters into arrangements for research and development, manufacturing and/or commercialization services. Such arrangements may require the Company to deliver various rights, services, including intellectual property rights/licenses, research and development services, and/or commercialization services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of nonrefundable upfront license fees, development and commercial performance milestone payments, royalty payments, consulting fees and/or profit sharing.

In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects the Company’s best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.

The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Should there be royalties, the Company utilizes the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.

Licensing Agreements

The Company enters into licensing agreements with licensees that fall under the scope of ASC 606.

The terms of the Company’s licensing agreements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related to the achievement of development, regulatory, or commercial goals; and (iii) royalties on net sales of licensed products. Each of these payments may result in licensing revenues.

As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may include such estimates as, independent evidence of market price, forecasted revenues or costs, development timelines, discount rates, and probability of regulatory success. The Company evaluates each performance obligation to determine if they can be satisfied at a point in time or over time, and it measures the services delivered to the licensee which are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated input component and, therefore revenue or expense recognized, would be recorded as a change in estimate. In addition, variable consideration (e.g., milestone payments) must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

Up-front Fees: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.

Milestone Payments: At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s or the licensee’s control, such as non-operational developmental and regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or the licensee’s control, such as operational developmental milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company’s estimate of the transaction price may also result in negative licensing revenues and earnings in the period of adjustment.

KP415 License Agreement

In September 2019, the Company entered into a Collaboration and License Agreement (the “KP415 License Agreement”) with Commave Therapeutics SA, an affiliate of Gurnet Point Capital (“Commave”). Under the KP415 License Agreement, the Company granted to Commave an exclusive, worldwide license to develop, manufacture and commercialize the Company’s product candidates containing SDX and d-methylphenidate (“d-MPH”), including AZSTARYS, KP484, and, at the option of Commave, KP879, KP922 or any other product candidate developed by the Company containing SDX and developed to treat ADHD or any other CNS disorder (the “Additional Product Candidates” and, collectively with AZSTARYS and KP484, the “Licensed Product Candidates”). Pursuant to the KP415 License Agreement, Commave (i) paid the Company an upfront payment of $10.0 million; (ii) agreed to pay milestone payments of up to $63.0 million upon the occurrence of specified regulatory milestones related to AZSTARYS and KP484; (iii) agreed to pay additional payments of up to $420.0 million upon the achievement of specified U.S. sales milestones; and (iv) has agreed to pay the Company quarterly, tiered royalty payments ranging from a percentage in the high single digits to the mid-twenties of Net Sales (as defined in the KP415 License Agreement) in the United States and a percentage in the low to mid-single digits of Net Sales in each country outside the United States, in each case subject to specified reductions under certain conditions as described in the KP415 License Agreement. Commave is obligated to make such royalty payments on a product-by-product basis until expiration of the royalty term for the applicable product.

In April 2021, the Company entered into Amendment No. 1 to the KP415 Amendment (the "KP415 Amendment"). Pursuant to the KP415 Amendment, the Company and Commave agreed to modify the compensation terms of the KP415 License Agreement. Pursuant to the KP415 Amendment, Commave paid the Company $10.0 million in connection with the entry into the KP415 Amendment as a result of the regulatory approval of AZSTARYS in the United States which occurred on March 2, 2021. Commave also paid the Company $10.0 million following the receipt of the scheduling determination of the compound SDX by the U.S. Drug Enforcement Agency (the "DEA"), which occurred on May 7, 2021. In addition, the KP415 Amendment increased the total remaining future regulatory and sales milestone payments related to AZSTARYS to up to an aggregate of $590.0 million in payments upon the occurrence of specified regulatory milestones related to AZSTARYS and upon the achievement of specified U.S. net sales milestones. Further, under the KP415 Amendment, Commave agreed to pay the Company quarterly, tiered royalty payments that are calculated from a base royalty rate percentage in the high single digits to the mid-twenties of net sales in the United States, subject to adjustment based on annual net sales, and a percentage in the low to mid-single digits of Net Sales in each country outside the United States, in each case subject to specified reductions under certain conditions, including with respect to the final approval label, as described in the KP415 License Agreement. Commave is obligated to make such royalty payments on a product-by-product basis until expiration of the royalty term for the applicable product.

Pursuant to the KP415 Amendment, Commave and the Company also agreed to modify Commave’s ROFR such that the Company’s product candidate, KP922, is no longer subject to Commave’ ROFR to acquire, license or commercialize any Additional Product Candidate. Commave’s ROFR shall only apply to any Additional Product Candidate which contains SDX, with such ROFR expiring upon the acceptance of an NDA for such Additional Product Candidate containing SDX.

Commave also agreed to be responsible for and reimburse the Company for all of the development, commercialization and regulatory expenses incurred on the licensed products, subject to certain limitations as set forth in the KP415 License Agreement. As part of this agreement the Company is obligated to perform consulting services on behalf of Commave related to the licensed products. For these consulting services, Commave has agreed to pay the Company a set rate per hour on any consulting services performed on behalf of Commave for the benefit of the licensed products.

In accordance with the terms of the Company’s March 20, 2012 Termination Agreement with Aquestive Therapeutics (formerly known as MonoSol Rx, LLC), Aquestive Therapeutics has the right to receive an amount equal to 10% of any royalty or milestone payments made to the Company related to AZSTARYS, KP484, KP879 or KP1077 under the KP415 License Agreement.

The KP415 License Agreement is within the scope of ASC 606, as the transaction represents a contract with a customer where the participants function in a customer / vendor relationship and are not exposed equally to the risks and rewards of the activities contemplated under the KP415 License Agreement. Using the concepts of ASC 606, the Company identified the grant of the exclusive, worldwide license and the performance of consulting services, which includes the reimbursement of out-of-pocket third-party research and development costs, as its only two performance obligations at inception. The Company further determined that the transaction price, at inception, under the agreement was $10.0 million upfront payment plus the fair value of the Development Costs (as defined in the KP415 License Agreement) which was allocated among the performance obligations based on their respective related stand-alone selling price.

The consideration allocated to the grant of the exclusive, worldwide license was $10.0 million, which reflects the standalone selling price. The Company utilized the adjusted market assessment approach to determine this standalone selling price which included analyzing prospective offers received from various entities throughout our licensing negotiation process as well as the consideration paid to other competitors in the market for a similar type of transaction. The Company determined that the intellectual property licensed under the KP415 License Agreement represented functional intellectual property and it has significant standalone functionality and therefore should be recognized at a point in time as opposed to over time. The revenue related to the grant of the exclusive, worldwide license was recognized at a point in time at the inception of the KP415 License Agreement.

The consideration allocated to the performance of consulting services, which includes the reimbursement of out-of-pocket third-party research and development costs, was the fair value of the Development Costs (as defined in the KP415 License Agreement), which reflects the standalone selling price. The Company utilized a blended approach which took into consideration the adjusted market assessment approach and the expected cost plus a margin approach to determine this standalone selling price. This blended approach utilized the adjusted market approach and expected cost plus margin approach to value the performance of consulting services which included analyzing hourly rates of vendors in the market who perform similar services to those of the Company to develop a range and then analyzing the average cost per hour of our internal resources and applying a margin which placed the value in the median of the previously identified range. For the reimbursement of out-of-pocket third-party research and development costs the Company utilized the expected cost plus a margin approach, which included estimating the actual out-of-pocket cost the Company expects to pay to third-parties for research and development costs and applying a margin, if necessary. The Company determined that no margin was necessary for these out-of-pocket third-party research and development costs as these are purely pass-through costs and the margin for managing these third-party activities is included within the value of the performance of consulting services. The Company determined that the performance of consulting services, including reimbursement of out-of-pocket third-party research and development costs, is a performance obligation that is satisfied over time as the services are performed and the reimbursable costs are paid. As such, the revenue related to the performance obligation will be recognized as the consulting services are performed and the services associated with the reimbursable out-of-pocket third-party research and development costs are incurred and paid by the Company, in accordance with the practical expedient allowed under ASC 606 regarding an entity’s right to consideration from a customer in an amount that corresponds directly to the value to the customer of the entity’s performance completed to date. As discussed above, the combination of the standalone selling price of these consulting services and certain out-of-pocket third-party research and development costs for AZSTARYS was the fair value of the Development Costs at inception. These Development Costs effectively created a cap on certain consulting services and out-of-pocket third-party research and development costs identified in the initial product development plan for AZSTARYS which was anticipated at the inception date of the KP415 License Agreement. As of December 31, 2020, the Company had recognized all of the consulting services and out-of-pocket third-party research and development costs under this cap.

Under the KP415 License Agreement, Commave was granted an exclusive right to first negotiation whereby upon completion of a Phase 1 proof-of-concept study, the Company and Commave may negotiate the economic terms under which certain Additional Products may be included as a Product (both as defined in the KP415 License Agreement) under the KP415 License Agreement (the “Additional Product Option”). In addition to the Additional Product Option, Commave was also granted a right of first refusal (“ROFR”) to acquire, license and/or commercialize any of the Additional Product Candidates should they choose not to exercise the Additional Product Option. Should Commave choose to exercise the Additional Product Option on any Additional Product Candidates, Commave and the Company shall negotiate in good faith regarding the economic terms of such Additional Product Candidate. Further, should Commave exercise the ROFR on any Additional Product Candidate, the economic terms of the agreement shall be the same as those offered to the third-party. Under ASC 606 an option to acquire additional goods or services gives rise to a performance obligation if the option provides a material right to the customer. The Company concluded that the above-described Additional Product Option and ROFR do not constitute material rights to the customer as Commave would acquire the goods or services at a to be negotiated price, which the Company expects to approximate fair value and therefore Commave would not receive a material discount on these goods or services compared to market rates.

The Company is entitled to additional payments from Commave conditioned upon the achievement of specified regulatory milestones related to AZSTARYS and KP484 and the achievement of certain U.S. sales milestones. Further, Commave will pay the Company quarterly, tiered royalty payments ranging from a percentage in the high single digits to mid-twenties of Net Sales (as defined in the KP415 License Agreement) in the United States and a percentage in the low to mid-single digits of Net Sales in each country outside of the U.S., in each case subject to specified reductions under certain conditions as described in the KP415 License Agreement. The Company concluded that these regulatory milestones, sales milestones and royalty payments each contain a significant uncertainty associated with a future event. As such, these milestone and royalty payments are constrained at contract inception and are not included in the transaction price as the Company could not conclude that it is probable a significant reversal in the amount of cumulative revenue recognized will not occur surrounding these milestone payments. At the end of each reporting period, the Company updates its assessment of whether the milestone and royalty payments are constrained by considering both the likelihood and magnitude of the potential revenue reversal.

For example, in May 2020, the FDA accepted the Company’s NDA for AZSTARYS. Per the KP415 License Agreement, the Company received a regulatory milestone payment of $5.0 million following the FDA’s acceptance of the AZSTARYS NDA. Since the FDA accepted the Company’s NDA for AZSTARYS the constraint was removed and revenue recognized. The associated revenue was allocated among the two performance obligations identified at contract inception. Since both performance obligations were satisfied as of the end of the second quarter of 2020 the full $5.0 million payment was recognized as revenue during the second quarter of 2020.

Per the KP415 Amendment, the Company earned a regulatory milestone payment of $10.0 million following the FDA’s approval of the AZSTARYS NDA, in March 2021, as well as $10.0 million following the DEA's scheduling of SDX in May 2021. Since the FDA approved the NDA for AZSTARYS and the DEA scheduled SDX, the constraints were removed and revenue recognized. The associated revenue was allocated among the two performance obligations identified at contract inception. Since both performance obligations were satisfied as of the end of each respective quarter of 2021, the full $10.0 million for each milestone was recognized as revenue in the statements of operations for the first quarter and second quarter of 2021, respectively. In accordance with ASC 340-40, Contracts with Customers, the Company recognized $1.0 million, respectively, of royalty costs due to payment to Aquestive related to the regulatory milestones earned and recorded it in the item titled royalty and direct contract acquisition costs in the statements of operations for first and second quarter of 2021.

For the years ended December 31, 2021, and 2020, the Company recognized revenue under the KP415 License Agreement of $20.9 million and $7.3 million, respectively. There was no deferred revenue related to this agreement as of December 31, 2021, or 2020.

Consulting Arrangements

The Company enters into consulting arrangements with third parties that fall under the scope of ASC 606. These arrangements may require the Company to deliver various rights, services, including research and development services, regulatory services and/or commercialization support services. The underlying terms of these arrangements generally provide for consideration to the Company in the form of consulting fees and reimbursements of out-of-pocket third-party research and development, regulatory and commercial costs.

Corium Consulting Agreement

In July 2020, the Company entered into a consultation services arrangement (the “Corium Consulting Agreement”) with Corium, Inc. (“Corium”) under which Corium engaged the Company to guide the product development and regulatory activities for certain current and potential future products in Corium’s portfolio, as well as continue supporting preparation for the potential commercial launch of AZSTARYS (together, “Corium Consulting Services”). Corium is a portfolio company of Gurnet Point Capital and was tasked by Commave to lead all commercialization activities for AZSTARYS under the KP415 License Agreement, as discussed above.

Under the Corium Consulting Agreement, the Company is entitled to receive payments from Corium of up to $15.6 million, $13.6 million of which will be paid in quarterly installments through March 31, 2022. The remaining $2.0 million was conditioned upon the approval by the FDA of the NDA for Corium's product candidate, ADLARITY. This $2.0 million was earned in the first quarter of 2022. Corium also agreed to be responsible for and reimburse the Company for all development, commercialization and regulatory expenses incurred as part of the performance of the Corium Consulting Services.

The Corium Consulting Agreement is within the scope of ASC 606, as the transaction represents a contract with a customer where the participants function in a customer / vendor relationship and are not exposed equally to the risks and rewards of the activities contemplated under the Corium Consulting Agreement. Using the concepts of ASC 606, the Company identified the performance of consulting services, which includes the reimbursement to the Company of third-party pass-through costs, as its only performance obligation at inception. The Company further determined that the transaction price, at inception, under the agreement was $13.6 million which is the fair value of the consulting services, including the reimbursement of third-party pass-through costs. The Company concluded that the regulatory milestone contains a significant uncertainty associated with a future event. As such, this milestone is constrained at contract inception and is not included in the transaction price as the Company could not conclude that it is probable a significant reversal in the amount of cumulative revenue recognized will not occur surrounding these milestone payments. At the end of each reporting period, the Company updates its assessment of whether the milestone is constrained by considering both the likelihood and magnitude of the potential revenue reversal.

The Company determined that the performance of consulting services, including reimbursement of third-party pass-through costs, is a performance obligation that is satisfied over time as the services are performed and the reimbursable costs are paid. As such, the revenue related to the performance obligation will be recognized as the consulting services are performed and the services associated with the reimbursable third-party pass-through costs are incurred and paid by the Company, in accordance with the practical expedient allowed under ASC 606 regarding an entity’s right to consideration from a customer in an amount that corresponds directly to the value to the customer of the entity’s performance completed to date. As of December 31, 2021, the Company has recognized approximately 85% of the consulting services and third-party pass-through costs under the Corium Consulting Agreement.

For the years ended December 31, 2021, and 2020, the Company recognized revenue under the Corium Consulting Agreement of $7.7 million and $3.9 million, respectively. As of December 31, 2021, and 2020, the Company had deferred revenue related to this agreement of $0.4 million and $0.1 million, respectively.

Other Consulting Arrangements

For the years ended December 31, 2021, and 2020, the Company recognized revenue under other consulting arrangements of $0.1 million and $1.7 million, respectively. There was no deferred revenue from other consulting arrangements as of December 31, 2021, or 2020.

Receivable [Policy Text Block]

Accounts and Other Receivables

Accounts and other receivables consist of receivables under the KP415 License Agreement and Corium Consulting Agreement, as well as receivables related to other consulting arrangements, income tax receivables and other receivables due to the Company. Receivables under the KP415 License Agreement and Corium Consulting Agreement are recorded for amounts due to the Company related to reimbursable third-party costs and performance of consulting services. These receivables, as well as the receivables related to other consulting arrangements, are evaluated to determine if any reserve or allowance should be established at each reporting date. As of December 31, 2021, the Company had receivables related to the Corium Consulting Agreement of $1.2 million, KP415 License Agreement of $0.1 million and other consulting arrangements of $0.1 million. As of December 31, 2020, the Company had receivables related to the Corium Consulting Agreement of $2.1 million and other consulting arrangements of $0.4 million. As of December 31, 2021, and 2020, no reserve or allowance for doubtful accounts has been established.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Major components of research and development costs include cash compensation, stock-based compensation, depreciation and amortization expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Costs incurred in research and development are expensed as incurred.

The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the statements of operations as the Company receives the related goods or services.

The Company enters into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with the applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when the Company has not yet been invoiced or otherwise notified of actual cost. The majority of the service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of the accrued expenses as of each balance sheet date based on the facts and circumstances known. The Company periodically confirms the accuracy of the estimates with the service providers and make adjustments, if necessary.

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative expenses on the statements of operations.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. Valuation allowances are recorded to reduce deferred tax assets to the amount the Company believes is more likely than not to be realized.

Uncertain tax positions are recognized only when the Company believes it is more likely than not that the tax position will be upheld on examination by the taxing authorities based on the merits of the position. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. The Company did not have any accrued interest or penalties associated with uncertain tax positions as of December 31, 2021, and 2020.

The Company files income tax returns in the United States for federal and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal and state and local income tax examinations for years prior to 2015, although carryforward attributes that were generated prior to 2017 may still be adjusted upon examination by the Internal Revenue Service if used in a future period. No income tax returns are currently under examination by taxing authorities.

Share-based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers and directors based on the estimated fair values of the awards as of the grant date. The Company records the value of the portion of the award that is ultimately expected to vest as expense over the requisite service period. The Company also accounts for equity instruments issued to non-employees using a fair value approach under Accounting Standards Codification ("ASC") subtopic 505-50. The Company values equity instruments and stock options granted using the Black-Scholes option pricing model.

Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted Net Loss per Share of Common Stock

The Company uses the two-class method to compute net loss per common share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock and select warrants are entitled to participate in distributions, when and if declared by the board of directors, that are made to common stockholders and, as a result, are considered participating securities.

Segment Reporting, Policy [Policy Text Block]

Segment and Geographic Information

Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is available and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company views its operations and manages its business as a single operating and reporting segment. All assets of the Company were held in the United States as of December 31, 2021, and 2020.

New Accounting Pronouncements, Policy [Policy Text Block]

Application of New or Revised Accounting Standards—Adopted

From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326)—Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This update applies to all entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial statements and disclosures.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820)—Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the FASB Concepts Statement, Conceptual Framework for Financial Reporting—Chapter 8: Notes to Financial Statements, which the FASB finalized on August 28, 2018, including the consideration of costs and benefits. This update applies to all entities that are required, under existing U.S. GAAP, to make disclosures about recurring or nonrecurring fair value measurements. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The adoption of ASU 2018-13 did not have a material impact on the Company’s financial statements and disclosures.

Application of New or Revised Accounting Standards—Not Yet Adopted

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40); Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which addresses issues identified as a result of the complexities associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. This update addresses, among other things, the number of accounting models for convertible debt instruments and convertible preferred stock, targeted improvements to the disclosures for convertible instruments and earnings-per-share (“EPS”) guidance and amendments to the guidance for the derivatives scope exception for contracts in an entity’s own equity, as well as the related EPS guidance. This update applies to all entities that issue convertible instruments and/or contracts in an entity’s own equity. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. FASB specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company does not believe the adoption of ASU 2020-06 will have a material impact on the Company’s financial statements and disclosures.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40); Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the FASB Emerging Issues Task Force (“ASU 2021-04”), which aims to clarify and reduce diversity in issuer's accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. This update applies to all entities that issue freestanding written call options that are classified in equity. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. FASB specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company does not believe the adoption of ASU 2021-04 will have a material impact on the Company’s financial statements and disclosures.

Note F - Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued interest	$ 0	$ 1,158
Accrued banking fees	700	700
Accrued severance	0	53
Accrued payroll	1,054	1,299
Accrued professional fees	259	1,639
Accounts payable	516	1,174
Other accrued expenses	509	624
Total accounts payable and accrued expenses	$ 3,038	$ 6,647

Note H - Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Amortization of right-of-use assets	$ 129	$ 124
Interest on lease liabilities	9	23
Total finance lease cost	138	147
Operating lease cost	365	363
Short-term lease cost	199	210
Variable lease cost	47	55
Less: sublease income	(91)	(106)
Total lease costs	$ 658	$ 669

Note I - Supply Arrangement (Details Textual) $ in Millions	12 Months Ended
Note I - Supply Arrangement (Details Textual) $ in Millions	Dec. 31, 2021	Dec. 31, 2020 USD ($)
Number of Manufacturing Arrangements	1	1
Supply Arrangement Expense		$ 3.2
Supply Arrangement, Automatic Renewal Period (Year)	2 years
Supply Arrangement, Period of Prior Notice (Month)	12 months

Note H - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2021

Lease, Cost [Table Text Block]

	*Year Ended December 31,*
Lease Cost	*2021*			*2020*
Finance lease cost:
Amortization of right-of-use assets	$	129		$	124
Interest on lease liabilities		9			23
Total finance lease cost		138			147
Operating lease cost		365			363
Short-term lease cost		199			210
Variable lease cost		47			55
Less: sublease income		(91	)		(106	)
Total lease costs	$	658		$	669

Schedule of Leases Cash Flow Information [Table Text Block]

	*Year Ended December 31,*
	*2021*		*2020*
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from finance leases	$	9	$	23
Financing cash flows from finance leases		173		227
Operating cash flows from operating leases		460		447
Operating cash flows from short-term leases		199		210
Operating cash flows from variable lease costs		47		55

Right-of-use assets obtained in exchange for lease liabilities:
Finance leases	$	-	$	17
Operating leases		-		20

Schedule of Leases Balance Sheet Information [Table Text Block]

	*December 31,*
	*2021*			*2020*
Finance Leases
Property and equipment, at cost	$	1,031		$	1,031
less: accumulated depreciation and amortization		(651	)		(523	)
Property and equipment, net	$	380		$	508

Other current liabilities	$	15		$	172
Other long-term liabilities		6			22
Total finance lease liabilities	$	21		$	194

Operating Leases
Operating lease right-of-use assets	$	1,141		$	1,350
Total operating lease right-of-use assets	$	1,141		$	1,350

Current portion of operating lease liabilities	$	356		$	327
Operating lease liabilities, less current portion		1,232			1,587
Total operating lease liabilities	$	1,588		$	1,914

Weighted Average Remaining Lease Term
Finance leases	1 year			1 year
Operating leases	4 years			5 years

Weighted Average Discount Rate
Finance leases		12.0	%		8.5	%
Operating leases		7.5	%		7.5	%

Operating and Finance Lease, Liability, Maturity [Table Text Block]

	*Finance*			*Operating*
Year Ending December 31,	*Leases*			*Leases*
2022	$	16		$	463
2023		7			472
2024		-			484
2025		-			390
2026		-			30
Thereafter		-			-
Total lease payments		23			1,839
Less: future interest expense		(2	)		(251	)
Lease liabilities	$	21		$	1,588

Note D - Prepaid Expenses and Other Current Assets - Components of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid insurance	$ 637	$ 453
Prepaid offering costs	293	825
Other prepaid expenses and current assets	252	203
Total prepaid expenses and other current assets	$ 1,182	$ 1,481

Note N - Income Taxes - Schedule of Reconciliation of Difference Between Benefit for Income Taxes and Income Taxes at Statutory U.S. Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Federal statutory rate	21.00%	21.00%
Change in valuation allowance	(28.39%)	(22.65%)
Return to provision and deferred true-up	(0.26%)	0.11%
Change in rate	3.00%	0.82%
State tax benefit (net of federal)	5.14%	3.51%
Warrant liability	(0.06%)	(0.30%)
Stock-based compensation	(2.68%)	(2.18%)
PPP Loan forgiveness	1.94%	0.00%
Other	(0.08%)	(0.05%)
Federal income tax provision effective rate	(0.39%)	0.26%

Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Equity Line of Credit [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Equity Line of Credit [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	Equity Line of Credit [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	Equity Line of Credit [Member] Undesignated Preferred Stock [Member]	Equity Line of Credit [Member] Common Stock [Member]	Equity Line of Credit [Member] Additional Paid-in Capital [Member]	Equity Line of Credit [Member] Treasury Stock [Member]	Equity Line of Credit [Member] Retained Earnings [Member]	Equity Line of Credit [Member]	Underwritten Public Offering [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Underwritten Public Offering [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	Underwritten Public Offering [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	Underwritten Public Offering [Member] Undesignated Preferred Stock [Member]	Underwritten Public Offering [Member] Common Stock [Member]	Underwritten Public Offering [Member] Additional Paid-in Capital [Member]	Underwritten Public Offering [Member] Treasury Stock [Member]	Underwritten Public Offering [Member] Retained Earnings [Member]	Underwritten Public Offering [Member]	Optional Exchange Principal Amount [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Optional Exchange Principal Amount [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	Optional Exchange Principal Amount [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	Optional Exchange Principal Amount [Member] Undesignated Preferred Stock [Member]	Optional Exchange Principal Amount [Member] Common Stock [Member]	Optional Exchange Principal Amount [Member] Additional Paid-in Capital [Member]	Optional Exchange Principal Amount [Member] Treasury Stock [Member]	Optional Exchange Principal Amount [Member] Retained Earnings [Member]	Optional Exchange Principal Amount [Member]	January 2021 Inducement Warrants [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	January 2021 Inducement Warrants [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	January 2021 Inducement Warrants [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	January 2021 Inducement Warrants [Member] Undesignated Preferred Stock [Member]	January 2021 Inducement Warrants [Member] Common Stock [Member]	January 2021 Inducement Warrants [Member] Additional Paid-in Capital [Member]	January 2021 Inducement Warrants [Member] Treasury Stock [Member]	January 2021 Inducement Warrants [Member] Retained Earnings [Member]	January 2021 Inducement Warrants [Member]	Warrants to Purchase Common Stock [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Warrants to Purchase Common Stock [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	Warrants to Purchase Common Stock [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	Warrants to Purchase Common Stock [Member] Undesignated Preferred Stock [Member]	Warrants to Purchase Common Stock [Member] Common Stock [Member]	Warrants to Purchase Common Stock [Member] Additional Paid-in Capital [Member]	Warrants to Purchase Common Stock [Member] Treasury Stock [Member]	Warrants to Purchase Common Stock [Member] Retained Earnings [Member]	Warrants to Purchase Common Stock [Member]	Exchange Warrants [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Exchange Warrants [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	Exchange Warrants [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	Exchange Warrants [Member] Undesignated Preferred Stock [Member]	Exchange Warrants [Member] Common Stock [Member]	Exchange Warrants [Member] Additional Paid-in Capital [Member]	Exchange Warrants [Member] Treasury Stock [Member]	Exchange Warrants [Member] Retained Earnings [Member]	Exchange Warrants [Member]	June 2021 Inducement Warrants [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	June 2021 Inducement Warrants [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	June 2021 Inducement Warrants [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	June 2021 Inducement Warrants [Member] Undesignated Preferred Stock [Member]	June 2021 Inducement Warrants [Member] Common Stock [Member]	June 2021 Inducement Warrants [Member] Additional Paid-in Capital [Member]	June 2021 Inducement Warrants [Member] Treasury Stock [Member]	June 2021 Inducement Warrants [Member] Retained Earnings [Member]	June 2021 Inducement Warrants [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Undesignated Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Common Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Treasury Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Retained Earnings [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Undesignated Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Common Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Treasury Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Retained Earnings [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series B-1 Convertible Preferred Stock [Member]	Preferred Stock [Member] Series B-2 Convertible Preferred Stock [Member]	Undesignated Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019																																																																																		$ 0	$ 0	$ 0	$ 0	$ 0	$ 171,258	$ 0	$ (245,714)	$ (74,456)
Net income (loss)																																																																																		0	0	0	0	0	0	0	(12,760)	(12,760)
Stock-based compensation expense																																																																																		0	0	0	0	0	2,491	0	0	2,491
Issuance of common stock	$ 0	$ 0	$ 0	$ 0	$ 0	$ 2,303	$ 0	$ 0	$ 2,303										$ 0	$ 0	$ 0	$ 0	$ 0	$ 15,863	$ 0	$ 0	$ 15,863
Recognition of deferred offering costs in connection with equity line of credit																																																																																		0	0	0	0	0	121	0	0	121
Offering expenses charged to equity																																																																																		0	0	0	0	0	(153)	0	0	(153)
Issuance of common stock in exchange for consulting services																																																																																		0	0	0	0	0	202	0	0	202
Cash paid in lieu of fractional shares in connection with 16-for-1 reverse stock split																																																																																		0	0	0	0	0	(23)	0	0	(23)
Balance at Dec. 31, 2020																																																																																		0	0	0	0	0	192,062	0	(258,474)	(66,412)
Net income (loss)																																																																																		0	0	0	0	0	0	0	(8,555)	(8,555)
Stock-based compensation expense																																																																																		0	0	0	0	0	2,436	0	0	2,436
Issuance of common stock										$ 0	$ 0	$ 0	$ 0	$ 1	$ 49,284	$ 0	$ 0	$ 49,285
Offering expenses charged to equity																																																																																		0	0	0	0	0	(1,124)	0	0	(1,124)
Issuance of common stock in exchange for consulting services																																																																																		0	0	0	0	0	302	0	0	302
Issuance of common stock in connection with the exercise of warrants in the January 2021 Inducement Transaction, net of discounts and commissions																												$ 0	$ 0	$ 0	$ 0	$ 1	$ 40,390	$ 0	$ 0	$ 40,391
Issuance of common stock in connection with the exercise of common stock warrants																																					$ 0	$ 0	$ 0	$ 0	$ 0	$ 30,819	$ 0	$ 0	$ 30,819										$ 0	$ 0	$ 0	$ 0	$ 1	$ 36,559	$ 0	$ 0	$ 36,560
Fair value of warrants issued																												0	0	0	0	0	38,437	0	0	38,437										$ 0	$ 0	$ 0	$ 0	$ 0	$ 15,990	$ 0	$ 0	$ 15,990	0	0	0	0	0	17,089	0	0	17,089
Issuance of stock as a result of conversion																																																																$ 0	$ 0	$ 29,056	$ 0	$ 0	$ 0	$ 0	$ 0	$ 29,056	$ 0	$ 0	$ (29,056)	$ 0	$ 1	$ 29,055	$ 0	$ 0	$ 0
Deemed dividend related the Inducement Transaction																												$ 0	$ 0	$ 0	$ 0	$ 0	$ (37,444)	$ 0	$ 0	$ (37,444)																			$ 0	$ 0	$ 0	$ 0	$ 0	$ (16,898)	$ 0	$ 0	$ (16,898)
Shares repurchased as part of the Share Repurchase Program																																																																																		0	0	0	0	0	0	(2,814)	0	(2,814)
Balance at Dec. 31, 2021																																																																																		$ 0	$ 0	$ 0	$ 0	$ 4	$ 396,957	$ (2,814)	$ (267,029)	$ 127,118

Note J - Preferred Stock and Warrants

12 Months Ended

Dec. 31, 2021

Preferred Stock [Text Block]

J.	Preferred Stock and Warrants

Authorized, Issued, and Outstanding Preferred Stock

As of December 31, 2021, the Company had 10,000,000 shares of authorized, unallocated and unissued preferred stock.

As of December 31, 2020, the Company had 10,000,000 shares of authorized preferred stock. The following shares of preferred stock were designated, issued and outstanding as of December 31, 2020:

	Shares Authorized	Shares Issued	Shares Outstanding
Series A convertible preferred stock, $0.0001 par value	9,578	9,577	—
Series B-1 convertible preferred stock, $0.0001 par value	1,576	1,576	—
Series B-2 convertible preferred stock, $0.0001 par value	27,000	27,000	—

In June 2021, the Company filed with the Secretary of State of the State of Delaware: (i) a Certificate of Elimination of Series A Convertible Preferred Stock, eliminating from the Company’s Certificate of Incorporation the 9,578 shares designated as Series A Convertible Preferred Stock; (ii) a Certificate of Elimination of Series B-1 Convertible Preferred Stock, eliminating from the Company’s Certificate of Incorporation the 1,576 shares designated as Series B-1 Convertible Preferred Stock; and (iii) a Certificate of Elimination of Series B-2 Convertible Preferred Stock, eliminating from the Company’s Certificate of Incorporation the 31,480 shares designated as Series B-2 Convertible Preferred Stock. As of December 31, 2021, no shares of preferred stock were designated, issued or outstanding.

Series B-2 Preferred Stock

Pursuant to the December 2020 Exchange Agreement, on January 12, 2021, the Company issued to the Facility Note Holders an aggregate of 31,476.98412 shares of its Series B-2 Preferred Stock and warrants exercisable for an aggregate of 3,632,019 shares of the Company’s common stock (the “Exchange Warrants”).

The Series B-2 Preferred Stock was convertible into an aggregate of 4,842,690 shares of the Company’s common stock upon issuance at a conversion price equal to $6.4999. No fractional shares of common stock will be issued in connection with the conversion of the Series B-2 Preferred Stock. Instead, for any such fractional share that would have otherwise been issued upon conversion of a share of Series B-2 Preferred Stock, the Company will round such fraction up to the next whole share.

Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Series B-2 Convertible Preferred Stock

On January 11, 2021, as a condition to the closing of the transactions contemplated by the December 2020 Exchange Agreement, the Company filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Convertible Preferred Stock (the “Series B-2 Certificate of Designation”) with the Secretary of State of the State of Delaware, setting forth the preferences, rights and limitations of the Series B-2 Preferred Stock.

Immediately following the closing of the Public Offering, pursuant to the terms of the December 2020 Exchange Agreement, the Company:

	●	exchanged approximately $31.5 million (the "Exchange") of the outstanding principal and accrued interest on the Facility Notes for (i) the Series B-2 Preferred Stock and (ii) the Exchange Warrants; and

	●	made a payment of approximately $30.3 million (the “Debt Payment”) in partial repayment of the remaining outstanding principal and accrued interest on the Facility Notes.

Upon the closing of the Exchange and related Debt Payment, the amendments to the Facility Agreement, the Notes and the Investors’ Rights Agreement, dated as of February 19, 2015, by and among the Company, Deerfield and the other parties signatory thereto, contemplated by the December 2020 Exchange Agreement that were conditional upon, among other things, the closing of the Public Offering, the filing of the Series B-2 Certificate of Designation and/or the approval for listing of the Company’s common stock, including the shares issuable upon conversion of the Series B-2 Preferred Stock and exercise of the Exchange Warrants, on the Nasdaq Capital Market, became effective on January 12, 2021.

In March 2021, all shares of Series B-2 Preferred Stock converted into 4,842,699 shares of common stock.

Note D - Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2021

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	*December 31,*
	*2021*		*2020*
Prepaid insurance	$	637	$	453
Prepaid offering costs		293		825
Other prepaid expenses and current assets		252		203
Total prepaid expenses and other current assets	$	1,182	$	1,481

Note E - Property and Equipment - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Minimum [Member]
Property and equipment, useful lives (Year)	3 years
Maximum [Member]
Property and equipment, useful lives (Year)	10 years
Laboratory Equipment [Member]
Property and equipment, useful lives (Year)	10 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property and equipment, useful lives (Year)	5 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property and equipment, useful lives (Year)	10 years
Computer and Hardware [Member] \| Minimum [Member]
Property and equipment, useful lives (Year)	3 years
Computer and Hardware [Member] \| Maximum [Member]
Property and equipment, useful lives (Year)	7 years
Leasehold Improvements [Member]
Property and equipment, useful lives (Year)	9 years

Note N - Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Text Block]

N.	Income Taxes

The Company’s financial statements include a total state tax expense of $34,000 and state tax benefit of $34,000 related to research and development credits on a loss before income taxes of approximately $8.5 million and $12.8 million for the years ended December 31, 2021, and 2020, respectively. A reconciliation of the difference between the (expense)/benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows (in thousands, except amounts pertaining to rate which are shown as a percentage):

	*Year ended December 31,*
	*2021*			*2020*
Federal statutory rate		21.00	%		21.00	%
Effect of:
Change in valuation allowance		(28.39	)		(22.65	)
Return to provision and deferred true-up		(0.26	)		0.11
Change in rate		3.00			0.82
State tax benefit (net of federal)		5.14			3.51
Warrant liability		(0.06	)		(0.30	)
Stock-based compensation		(2.68	)		(2.18	)
PPP Loan forgiveness		1.94			-
Other		(0.08	)		(0.05	)
Federal income tax provision effective rate		(0.39	)%		0.26	%

The components of deferred tax assets and liabilities are as follows (in thousands):

	*December 31,*
	*2021*			*2020*
Deferred tax assets relating to:
Net operating loss carryforwards	$	60,977		$	59,050
Research and development tax carryforward		6,411			6,411
Stock-based compensation		4,807			4,219
Right-of-use liability		424			527
Property and equipment		14			18
Other deferred tax assets		288			343
Total gross deferred tax assets		72,921			70,568
Deferred tax liabilities relating to:
Right-of-use asset		(401	)		(464	)
Other deferred tax liabilities		(9	)		(12	)
Total gross deferred tax liabilities		(410	)		(476	)
Deferred tax assets less liabilities		72,511			70,092
Valuation allowance		(72,511	)		(70,092	)
Net deferred tax asset (liability)	$	-		$	-

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income (losses) and projections for future taxable income (losses) over the periods in which the deferred tax assets are deductible, management believes it is more likely than not that the Company will not realize the benefits of these deductible differences in the future.

The Company had the following federal net operating loss carryforward and research activities credits as of December 31, 2021 (in thousands):

	*Net Operating*		*Research*
Year Incurred	*Loss CF*		*Activities Cr.*		*Expiration*
2007	$	454	$	30		2027
2008		1,178		65		2028
2009		3,060		176		2029
2010		3,423		149		2030
2011		9,929		176		2031
2012		-		170		2032
2013		4,353		133		2033
2014		15,897		894		2034
2015		23,496		598		2035
2016		41,580		745		2036
2017		34,776		652		2037
2018		56,099		2,271		Indefinite
2019		22,922		352		Indefinite
2020		8,784		-		Indefinite
2021		7,328		-		Indefinite
	$	233,279	$	6,411

The Company also has certain state net operating loss carryforwards totaling $219.0 million, $142.4 million of which, if not utilized, will begin to expire in 2027 and $76.6 million of which have no expiration date. Due to potential ownership changes that may have occurred or would occur in the future, Internal Revenue Code Section 382 may place additional limitations on the Company’s ability to utilize the net operating loss carryforward.

ASC 740-10, Accounting for Uncertainty in Income Taxes, uses the term “more likely than not” to evaluate whether or not a tax position will be sustained upon examination. The Company has not identified any tax positions that do not meet the more likely than not threshold.

On March 27, 2020, the CARES Act was enacted into law in response to the COVID-19 pandemic. The Company has evaluated the various income and payroll tax provisions and expects little or no impact to income tax expense.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Note A - Description of Business and Basis of Presentation (Details Textual) $ / shares in Units, $ in Thousands							1 Months Ended	4 Months Ended
	Dec. 31, 2021 USD ($) $ / shares shares	Jul. 12, 2021 USD ($)	Feb. 01, 2021 shares	Jan. 12, 2021 USD ($) $ / shares shares	Jan. 08, 2021 $ / shares shares	Dec. 23, 2020 $ / shares	Feb. 29, 2020 USD ($) shares	May 31, 2020 USD ($) shares	Dec. 20, 2021 USD ($)	Jul. 02, 2021 USD ($)	Feb. 03, 2021 shares	Dec. 31, 2020 USD ($) $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.0001					$ 0.0001						$ 0.0001
Sale of Stock, Authorized Amount \| $		$ 350,000
Stock Repurchase Program, Authorized Amount \| $									$ 50,000
Treasury Stock, Value, Ending Balance \| $	$ 2,814											$ (0)
Share Repurchase Program [Member]
Treasury Stock, Shares, Ending Balance (in shares)	320,161
Treasury Stock, Value, Ending Balance \| $	$ 2,800
Lincoln Park [Member]
Sale of Securities, Value, Available to Issue \| $							$ 4,000
Purchase Agreement, Term (Month)							12 months
Purchase Agreement, Additional Shares to Be Issued as Commitment Shares (in shares)							19,289
Purchase Agreement, Maximum Shares to be Issued (in shares)							579,260
Stock Issued During Period, Shares, New Issues (in shares)								559,971
Proceeds from Issuance of Common Stock \| $								$ 2,300
Roth Capital Partners, LLC [Member] \| Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				926,844	926,844
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 0.0001
Roth Capital Partners, LLC [Member] \| Public Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				12,078,361	7,692,307
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 6.50	$ 6.50
Class of Warrant or Right, Offering Price, Per Related Warrant (in dollars per share) \| $ / shares					$ 0.0001
Roth Capital Partners, LLC [Member] \| Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				806,932	754,035						18,702
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares				$ 8.125
Over Allotment Options, Number of Shares for Warrants (in shares)					1,153,846
Roth Capital Partners, LLC [Member] \| Underwriting Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					6,765,463
Shares and Warrants Issued, Price Per Share (in dollars per share) \| $ / shares					$ 6.50
Shares Issued, Price Per Share (in dollars per share) \| $ / shares					$ 6.4999
Proceeds from Issuance or Sale of Equity, Total \| $				$ 52,400
Roth Capital Partners, LLC [Member] \| Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)			374,035
Purchase Agreement Optional Period to Shares (Day)					45 days
Purchase Agreement, Maximum, Additional Shares Available for Purchase During the Optional Period (in shares)					1,153,846
JMP and RBCCM [Member] \| ATM Agreement Sales [Member]
Stock Issued During Period, Shares, New Issues (in shares)	0
Equity Distribution Agreement, Maximum Aggregate Offering Price \| $										$ 75,000
Equity Distribution Agreement, Commission Fee, Percentage of Gross Sales										3.00%
Stock Issued During Period, Value, New Issues \| $		$ 75,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio						16

Note P - Severance Expense (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 29, 2020	Dec. 31, 2021	Dec. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expense			$ 2,436	$ 2,491
Severance Expense [Member]
Share-based Payment Arrangement, Expense			$ 0	420
Employee Severance [Member] \| Accounts Payable and Accrued Liabilities [Member]
Accrued Severance Expense		$ 0		$ 100
Employee Severance [Member] \| Severance Expense [Member]
Severance Charges	$ 400	$ 0
Share-based Payment Arrangement, Expense	$ 400

Note F - Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2021

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

F.	Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following (in thousands):

	*December 31,*
	*2021*		*2020*
Accrued interest	$	-	$	1,158
Accrued banking fees		700		700
Accrued severance		-		53
Accrued payroll		1,054		1,299
Accrued professional fees		259		1,639
Accounts payable		516		1,174
Other accrued expenses		509		624
Total accounts payable and accrued expenses	$	3,038	$	6,647

Note O - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive securities (in shares)	5,495,229	1,248,690
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	0	81,101
January 2020 Note [Member]
Antidilutive securities (in shares)	0	34,615
The 2019 Notes [Member]
Antidilutive securities (in shares)	0	625,747
Share-based Payment Arrangement [Member]
Antidilutive securities (in shares)	1,273,879	355,785
Warrants to Purchase Common Stock [Member]
Antidilutive securities (in shares)	4,221,350	151,442

Note L - Stock-based Compensation - Nonvested Stock Option Awards (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of unvested shares (in shares)	966,664	164,651
Exercise Price Range One [Member]
Lower range (in dollars per share)	$ 2.848
Upper range (in dollars per share)	$ 10.00
Number of unvested shares (in shares)	861,139	82,247
Exercise Price Range Two [Member]
Lower range (in dollars per share)	$ 10.01
Upper range (in dollars per share)	$ 30.00
Number of unvested shares (in shares)	60,000	0
Exercise Price Range Three [Member]
Lower range (in dollars per share)	$ 30.01
Upper range (in dollars per share)	$ 50.00
Number of unvested shares (in shares)	36,190	54,300
Exercise Price Range Four [Member]
Lower range (in dollars per share)	$ 50.01
Upper range (in dollars per share)	$ 70.00
Number of unvested shares (in shares)	0	9,429
Exercise Price Range Five [Member]
Lower range (in dollars per share)	$ 70.01
Upper range (in dollars per share)	$ 327.20
Number of unvested shares (in shares)	9,335	18,675

Note K - Common Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jan. 26, 2021	Jan. 12, 2021	Oct. 25, 2018	Jun. 02, 2014	Jan. 31, 2021	Dec. 31, 2021	Jun. 18, 2021	Dec. 31, 2021	Dec. 31, 2020	Feb. 03, 2021	Jan. 08, 2021	Dec. 31, 2019
Common Stock, Shares Authorized (in shares)						250,000,000		250,000,000	250,000,000
Common Stock, Shares, Issued, Total (in shares)						35,325,801		35,325,801	4,537,321
Common Stock, Shares, Outstanding, Ending Balance (in shares)						35,005,640		35,005,640	4,537,321			2,271,882
Stock Issued During Period, Shares, Warrant Exercises (in shares)								18,772,510
Proceeds from Warrant Exercises								$ 30,819	$ 0
Preferred Stock Dividends and Other Adjustments, Total								54,342	(0)
Other Noncurrent Assets [Member]
Contract with Customer, Asset, after Allowance for Credit Loss, Total						$ 400		$ 400	$ 400
Deerfield Warrant [Member]
Class of Warrant or Right Issued (in shares)				14,423,076
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 46.25						$ 38.34		$ 93.60
Deerfield Warrant [Member] \| Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				1,923,077					120,192
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 46.25			$ 5.85			$ 38.34		$ 93.60
Warrant Issued to KVK [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			500,000						31,250
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 2.30						$ 36.80
Class of Warrant or Right, Additional Shares Exercisable for Each Milestones (in shares)			125,000
Pre-funded Warrants [Member] \| Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		926,844									926,844
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001
Stock Issued During Period, Shares, Warrant Exercises (in shares)					926,841
Proceeds from Warrant Exercises					$ 72,000
Public Offering Warrants [Member] \| Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		12,078,361									7,692,307
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.50									$ 6.50
Stock Issued During Period, Shares, Warrant Exercises (in shares)								3,030,881
Proceeds from Warrant Exercises								$ 16,900
Warrants and Rights Outstanding, Term (Year)		5 years
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise		4.99%
Class of Warrants or Right, Exercised During Period (in shares)								3,461,858
Underwriter Warrants [Member] \| Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		806,932								18,702	754,035
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 8.125
Stock Issued During Period, Shares, Warrant Exercises (in shares)								400,000
Proceeds from Warrant Exercises								$ 3,300
Class of Warrants or Right, Exercised During Period (in shares)								400,000
Over Allotment Options, Percentage of Common Stock Outstanding for Warrants		5.00%
Existing Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,620,358
Proceeds from Warrant Exercises	$ 44,000
Placement Agent Fee, Percentage	6.00%
January 2021 Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	7,944,430						6,117,509
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 6.36
Stock Issued During Period, Shares, Warrant Exercises (in shares)								1,676,921
Proceeds from Warrant Exercises						$ 10,700	$ 39,100
Warrants and Rights Outstanding, Term (Year)	5 years
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise	4.99%
Class of Warrants or Right, Exercised During Period (in shares)								1,676,921
Warrants Issued Upon Exchange, Percentage of Shares Issued Upon Exercise	120.00%
Class of Warrant, Purchase Price Per Warrant (in dollars per share)	$ 0.125
Placement Agent Fee, Percentage							6.00%
Maximum Percent of Common Stock Ownership Allowed Per Holder After Warrant Exercise Upon Holders Selection	9.99%
Preferred Stock Dividends and Other Adjustments, Total								$ 37,400
June 2021 Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							1,529,379
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 16.50
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise							4.99%
Class of Warrants or Right, Exercised During Period (in shares)								0
Warrants Issued Upon Exchange, Percentage of Shares Issued Upon Exercise							25.00%
Class of Warrant, Purchase Price Per Warrant (in dollars per share)							$ 0.125
Maximum Percent of Common Stock Ownership Allowed Per Holder After Warrant Exercise Upon Holders Selection							9.99%
Preferred Stock Dividends and Other Adjustments, Total								$ 16,900

Note C - Accounts and Other Receivables - Accounts and Other Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accounts receivable	$ 1,421	$ 2,442
Other receivables	107	137
Total accounts and other receivables	$ 1,528	$ 2,579

Note Q - Employee Benefit Plan

12 Months Ended

Dec. 31, 2021

Compensation and Employee Benefit Plans [Text Block]

Q.	Employee Benefit Plan

The Company has a 401(k) retirement plan (the “401(k) Plan”) that covers substantially all employees. The Company may provide a discretionary match with a maximum amount of 4% of the participant’s compensation, which vests immediately. The Company made matching contributions under the 401(k) Plan of $164,000 and $145,000 for the years ended December 31, 2021, and 2020, respectively.

The Company has a discretionary profit sharing plan (the “Profit Sharing Plan”) that covers all employees. Employees become eligible participants in the Profit Sharing Plan once they have provided three years of service to the Company. The Company made no contributions to the Profit Sharing Plan in 2021 or 2020.

Note M - Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Text Block]

M.	Fair Value of Financial Instruments

The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, long-term investments and accounts payable and accrued expenses, approximate their respective fair values due to the short-term nature of such instruments.

The fair values of the Deerfield Convertible Note, December 2019 Notes and the January 2020 Note were $7.3 million, $56.2 million and $3.1 million, respectively, as of December 31, 2020. The Deerfield Convertible Note, December 2019 Notes and the January 2020 Note were all extinguished in the first quarter of 2021 and therefore had no value as of December 31, 2021. The Deerfield Convertible Note, December 2019 Notes and the January 2020 Note fell within Level 3 of the fair value hierarchy as their value was based on the credit worthiness of the Company, which was an unobservable input. The Company used a Tsiveriotis-Fernandes model to value the Deerfield Convertible Note, December 2019 Notes and the January 2020 Note as of December 31, 2020.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2021, and 2020 (in thousands):

			Quoted Prices		Significant
			in Active		Other		Significant
	*Balance at*		*Markets for*		*Observable*		*Unobservable*
	*December 31,*		*Identical Assets*		*Inputs*		*Inputs*
	*2021*		*(Level 1)*		*(Level 2)*		*(Level 3)*
Deerfield Warrant liability	$	288	$	-	$	-	$	288
Embedded Warrant Put Option		18		-		-		18
KVK Warrant liability		24		-		24		-
Total liabilities	$	330	$	-	$	24	$	306
Trading securities:
U.S. government-sponsored agency securities	$	4,997	$	-	$	4,997	$	-
Certificates of deposit		490		490		-		-
U.S. Treasury securities		9,935		9,935		-		-
Total assets	$	15,422	$	10,425	$	4,997	$	-

			*Quoted Prices*		*Significant*
			*in Active*		*Other*		*Significant*
	*Balance at*		*Markets for*		*Observable*		*Unobservable*
	*December 31,*		*Identical Assets*		*Inputs*		*Inputs*
	*2020*		*(Level 1)*		*(Level 2)*		*(Level 3)*
Deerfield Warrant liability	$	230	$	-	$	-	$	230
Embedded Warrant Put Option		25		-		-		25
Deerfield Note Conversion Feature		-		-		-		-
KVK Warrant liability		49		-		49		-
Total liabilities	$	304	$	-	$	49	$	255

The Company’s Deerfield Warrant liability, embedded Warrant Put Option and trading securities are, and the embedded Deerfield Note Put Option was, measured at fair value on a recurring basis. As of December 31, 2021, the Deerfield Warrant liability and embedded Warrant Put Option, and as of December 31, 2020, the Deerfield Warrant liability, embedded Warrant Put Option and the embedded Deerfield Note Conversion Feature were, reported on the balance sheets in derivative and warrant liability. As of December 31, 2021, the trading securities are reported on the balance sheets in long-term investments. The Company used a Monte Carlo simulation to value the Deerfield Warrant liability, embedded Warrant Put Option and the embedded Deerfield Note Conversion Feature for all periods presented. Significant unobservable inputs used in measuring the fair value of these financial instruments included the Company’s estimated enterprise value, an estimate of the timing of a liquidity or fundamental change event and a present value discount rate. Changes in the fair value of the Deerfield Warrant liability and embedded Warrant Put Option are, and changes in the fair value of the embedded Deerfield Note Put Option were (through December 31, 2020), reflected in the statements of operations for the years ended December 31, 2021, and 2020, as a fair value adjustment related to derivative and warrant liability.

The derivative liability for the Deerfield Warrant was $288,000 and $230,000 at December 31, 2021 and 2020, respectively. The derivative liability for the embedded Warrant Put Option was $18,000 and $25,000 at December 31, 2021 and 2020, respectively. The derivative liability for the Deerfield Note Conversion Feature had no value at December 31, 2020. A 10% increase in the enterprise value would result in an increase of $50,000 in the estimated fair value of the Deerfield Warrant liability and an increase of $3,000 in the estimated fair value of the embedded Warrant Put Option liability. In addition, the Company assumed a weighted-average probability of a liquidity event occurring of approximately 23% with an estimated probability-weighted value of approximately $55.0 million and a weighted-average probability of a fundamental change event occurring of approximately 34% with an estimated probability-weighted value of approximately $680 million, respectively, with estimated timing in each scenario of the first quarter of 2023.

The Company’s KVK Warrant liability is measured at fair value on a recurring basis. As of December 31, 2021, and 2020, the KVK Warrant liability is reported on the balance sheets in derivative and warrant liability. The Company estimates the fair value of the KVK Warrant using a probability-weighted Black-Scholes option-pricing model, which requires the use of subjective assumptions, including the expected term of the warrant, the expected stock price volatility, expected dividend yield and the risk-free interest rate for the expected term of the warrant. The expected term represents the period of time the warrant is expected to be outstanding. For the KVK Warrant, the Company used an expected term equal to the contractual term of the warrant. Expected volatility is based on the Company's historical volatility since the IPO. The Company assumes no dividend yield because dividends are not expected to be paid in the near future, which is consistent with the Company’s history of not paying dividends. Changes in the fair value of the KVK Warrant liability are reflected in the statements of operations for the years ended December 31, 2021, and 2020, as a fair value adjustment related to derivative and warrant liability.

A reconciliation of the beginning and ending balances for the derivative and warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):

	*2021*		*2020*
Balance as of beginning of period	$	255	$	96
Adjustment to fair value		51		159
Balance as of end of period	$	306	$	255

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note H - Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Commitments and Contingencies Disclosure [Text Block]

H.	Commitments and Contingencies

Legal Matters

From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not probable, or the amount cannot be reasonably estimated and, therefore, an accrual has not been made. However, for such matters when it is probable that the Company has incurred a liability and can reasonably estimate the amount, the Company accrues and discloses such estimates. As of December 31, 2021, and 2020, no accruals have been made related to commitments and contingencies.

Lease Agreements

The Company has operating and finance leases for office space, laboratory facilities and various laboratory equipment, furniture and office equipment and leasehold improvements. The Company's leases have remaining lease terms of less than 1 year to approximately 4 years, some of which include options to extend the leases for up to 5 years, and some which include options to terminate the leases within 1 year.

Florida

The Company leases office space in Florida, comprised of two contiguous office suites, under non-cancelable operating leases, which expire in August 2025 and February 2026, as to each space respectively, and include the right to extend the term of the leases for two successive five-year terms upon expiration.

In February 2020, the Company agreed to sublease office space in Florida, comprised of one of the two contiguous suites, under a non-cancelable operating lease, which expires in February 2026. In October 2020, the Company agreed to terminate this sublease, in exchange for a termination payment, due to financial difficulties encountered by the subtenant as a result of COVID-19.

Effective June 1, 2021, the Company agreed to sublease office space in Florida, comprised of one of the two contiguous suites, under a non-cancelable operating lease, which expires in February 2026.

Iowa

The Company leases office and laboratory facilities in Iowa under a non-cancelable operating lease. The Company’s lease for its Iowa facilities expires in September 2022 and includes a renewal option that could extend the lease for successive one-year terms upon expiration.

Virginia

The Company leases office and laboratory facilities in Virginia under a non-cancelable operating lease. The Company’s lease for its Virginia facilities expires in August 2022.

North Carolina

The Company leases office space in North Carolina under a non-cancelable operating lease. The Company's lease for its North Carolina facilities expires in March 2022.

Finance Lease

The Company leases various laboratory equipment, furniture and office equipment and leasehold improvements that are accounted for as finance leases and that require ongoing payments, including interest expense. The finance leases are financed through various financial institutions and are collateralized by the underlying assets. As of December 31, 2021, and 2020, the interest rates for assets under remaining finance leases range from 7.19% to 14.34%.

The components of lease expense were as follows (in thousands):

	*Year Ended December 31,*
Lease Cost	*2021*			*2020*
Finance lease cost:
Amortization of right-of-use assets	$	129		$	124
Interest on lease liabilities		9			23
Total finance lease cost		138			147
Operating lease cost		365			363
Short-term lease cost		199			210
Variable lease cost		47			55
Less: sublease income		(91	)		(106	)
Total lease costs	$	658		$	669

Rent expense for non-cancelable operating leases was $0.6 million and $0.6 million for the years ended December 31, 2021, and 2020, respectively.

Supplemental cash flow information related to leases was as follows (in thousands):

	*Year Ended December 31,*
	*2021*		*2020*
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from finance leases	$	9	$	23
Financing cash flows from finance leases		173		227
Operating cash flows from operating leases		460		447
Operating cash flows from short-term leases		199		210
Operating cash flows from variable lease costs		47		55

Right-of-use assets obtained in exchange for lease liabilities:
Finance leases	$	-	$	17
Operating leases		-		20

Supplemental balance sheet information related to leases was as follows (in thousands, except weighted average remaining lease term and weighted average discount rate):

	*December 31,*
	*2021*			*2020*
Finance Leases
Property and equipment, at cost	$	1,031		$	1,031
less: accumulated depreciation and amortization		(651	)		(523	)
Property and equipment, net	$	380		$	508

Other current liabilities	$	15		$	172
Other long-term liabilities		6			22
Total finance lease liabilities	$	21		$	194

Operating Leases
Operating lease right-of-use assets	$	1,141		$	1,350
Total operating lease right-of-use assets	$	1,141		$	1,350

Current portion of operating lease liabilities	$	356		$	327
Operating lease liabilities, less current portion		1,232			1,587
Total operating lease liabilities	$	1,588		$	1,914

Weighted Average Remaining Lease Term
Finance leases	1 year			1 year
Operating leases	4 years			5 years

Weighted Average Discount Rate
Finance leases		12.0	%		8.5	%
Operating leases		7.5	%		7.5	%

Maturities on lease liabilities were as follows (in thousands):

	*Finance*			*Operating*
Year Ending December 31,	*Leases*			*Leases*
2022	$	16		$	463
2023		7			472
2024		-			484
2025		-			390
2026		-			30
Thereafter		-			-
Total lease payments		23			1,839
Less: future interest expense		(2	)		(251	)
Lease liabilities	$	21		$	1,588

Note G - Debt Obligations

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Text Block]

G.	Debt Obligations

As of December 31, 2021, the Company had no convertible notes outstanding. As of December 31, 2020, the Company had convertible notes outstanding in the aggregate principal amount of $68.2 million.

Deerfield Facility Agreement

In June 2014, the Company entered into a $60 million multi-tranche credit facility (the “Deerfield Facility Agreement”) with Deerfield Private Design Fund III, LP (“Deerfield”). At the time the Company entered into the Deerfield Facility Agreement, the Company borrowed the first tranche, which consisted of a term loan of $15 million (the “Term Note”) and a senior secured loan of $10 million (the “Deerfield Convertible Note”). Deerfield was able to convert any portion of the outstanding principal and any accrued but unpaid interest on the Deerfield Convertible Note into shares of the Company’s common stock at an initial conversion price of $5.85 per share (the “Deerfield Note Put Option”). After giving effect to the Reverse Stock Split effected in December 2020, the conversion price became $93.60.

The Deerfield Convertible Note originally bore interest at 9.75% per annum but was subsequently reduced to 6.75%. Interest accrued on the outstanding balance under the Deerfield Convertible Note was due quarterly in arrears. The Company originally had to repay one-third of the outstanding principal amount of the Deerfield Convertible Note on the fourth and fifth anniversaries of the Deerfield Facility Agreement ( June 2018 and June 2019). In June 2018, Deerfield agreed to convert approximately $3.3 million of the principal amount then due, plus approximately $0.2 million of accrued interest, into 37,410 shares of our common stock (as discussed below in the section entitled “Facility Agreement Waiver and Fifth Amendment to Senior Secured Convertible Note”). In September 2019, the Company entered into an amendment with Deerfield in order to (i) reduce the interest rate applicable under the Deerfield Facility Agreement from 9.75% to 6.75%, (ii) provide for “payment in kind” of interest on the Loans (as defined in the Deerfield Facility Agreement), and (iii) defer the Loan payments due pursuant to the Deerfield Facility Agreement until June 1, 2020 (as discussed below in the section entitled “2021 Note Exchange Effected in September 2019”). In December 2019, the Company entered into another amendment with Deerfield in order to (i) defer the Loan payments due pursuant to the Deerfield Facility Agreement until March 31, 2021, and (ii) allow for the entries of additional debt and debt holders under the Deerfield Facility Agreement (as discussed below in the section entitled “2021 Note Exchange Effected in December 2019”). The Company was also obligated to repay principal of the Deerfield Convertible Note in the amount of approximately $7.0 million plus any capitalized interest to date on March 31, 2021. Prepayment of the outstanding balance was not allowed without written consent of Deerfield.

Pursuant to the Deerfield Facility Agreement, the Company issued to Deerfield a warrant to purchase 14,423,076 shares of Series D Preferred at an initial exercise price of $0.78 per share, which is exercisable until June 2, 2024 (the “Deerfield Warrant”). Upon completion of the Company’s initial public offering, the Deerfield Warrant automatically converted into a warrant to purchase 1,923,077 shares of the Company’s common stock at an exercise price of $5.85 per share. After giving effect to the Reverse Stock Split effected in December 2020, the shares issuable upon conversion of the warrant became 120,192 shares of common stock, and the exercise price of the Deerfield Warrant became $93.60 per share, which in January 2021 and June 2021 was further adjusted to $46.25 and $38.34 per share, respectively, in connection with the Company entering into the January 2021 and June 2021 Inducement Transactions (as defined in Note K) each of which triggered the anti-dilution provisions of the Deerfield Warrant. This warrant qualifies as a participating security under ASC Topic 260, Earnings per Share, and is treated as such in the net loss per share calculation (Note O). If a Major Transaction occurs (as defined in the Deerfield Facility Agreement) Deerfield may require the Company to redeem the Deerfield Warrant for a cash amount equal to the Black-Scholes value of the portion of the Deerfield Warrant to be redeemed (the “Warrant Put Option”).

The Company recorded the fair value of the shares of Series D Preferred to debt issuance costs on the date of issuance. The Company also recorded the fair value of the Deerfield Warrant and the embedded Warrant Put Option to debt discount on the date of issuance. The debt issuance costs and debt discount were amortized over the term of the related debt and the expense was recorded as interest expense related to amortization of debt issuance costs and discount in the statements of operations. In the first quarter of 2021, the debt was extinguished, through a series of debt payments and a conversion of debt principal and interest to Series B-2 Preferred Stock. As a result of the debt extinguishment, the associated discount and debt issuance costs were written off and recorded as a loss on extinguishment.

Pursuant to the Deerfield Facility Agreement, the Company was not able to enter into specified transactions, including a debt financing in the aggregate value of $750,000 or more, other than permitted indebtedness under the Deerfield Facility Agreement, a merger, an asset sale or any other change of control transaction or any joint venture, partnership or other profit-sharing arrangement, without the prior approval of the Required Lenders (as defined in the Deerfield Facility Agreement). Additionally, if the Company were to enter into a major transaction, including a merger, consolidation, sale of substantially all of its assets or other change of control transaction, Deerfield would have had the ability to demand that prior to consummation of such transaction the Company repay all outstanding principal and accrued interest of any notes issued under the Deerfield Facility Agreement. Under each warrant issued pursuant to the Deerfield Facility Agreement, Deerfield has the right to demand that the Company redeem the warrant for a cash amount equal to the Black-Scholes value of a portion of the warrant upon the occurrence of specified events, including a merger, an asset sale or any other change of control transaction.

Issuance of 5.50% Senior Convertible Notes and Third Amendment to Senior Secured Convertible Note and Warrant

In February 2016, the Company issued $86.3 million aggregate principal amount of its 5.50% Senior Convertible Notes due 2021 (the “2021 Notes”) to Cowen and RBC Capital Markets, LLC, as representatives of the several initial purchasers (the “Initial Purchasers”), who subsequently resold the 2021 Notes to qualified institutional buyers (the “Note Offering”) in reliance on the exemption from registration provided by Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

The 2021 Notes were issued pursuant to an indenture, dated as of February 9, 2016 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee (the “Trustee”). Interest on the 2021 Notes was payable semi-annually in cash in arrears on February 1 and August 1 of each year, beginning on August 1, 2016, at a rate of 5.50% per year. The 2021 Notes had an original maturity of February 1, 2021 unless earlier converted or repurchased.

The net proceeds from the Note Offering were approximately $82.8 million, after deducting the Initial Purchasers’ discount and estimated offering expenses. Concurrent with the Note Offering, the Company used approximately $18.6 million of the net proceeds from the Note Offering to repay in full the Term Note, plus all accrued but unpaid interest, a make-whole interest payment and a prepayment premium on the Term Note.

The 2021 Notes were not redeemable prior to the maturity date, and no sinking fund was provided for the 2021 Notes. The 2021 Notes were convertible at an initial conversion rate of 58.4454 shares of the Company’s common stock per $1,000 principal amount of the 2021 Notes, subject to adjustment under the Indenture, which is equal to an initial conversion price of approximately $17.11 per share of common stock. After giving effect to the Reverse Stock Split effected in December 2020, the conversion rate of the 2021 Notes would have been approximately 3.6528 shares of the Company’s common stock per $1,000 principal amount of the 2021 Notes, which is equal to a conversion price of approximately $273.76 per share.

If the Company underwent a “fundamental change” (as defined in the Indenture), holders could have required that the Company repurchase for cash all or any portion of their 2021 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2021 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Indenture included customary terms and covenants, including certain events of default after which the 2021 Notes may have become due and payable immediately.

As described in more detail below, in multiple exchanges occurring in December 2019 and January 2020, all outstanding 2021 Notes were exchanged by the holders thereof for either shares of our common stock or senior secured convertible promissory notes issued under the terms of the Deerfield Facility Agreement.

2021 Note Exchange Effected in December 2019

In December 2019, the Company entered into the December 2019 Exchange Agreement and Amendment to Facility Agreement, Senior Secured Convertible Notes and Warrants (the “December 2019 Exchange Agreement”) with the Deerfield Lenders and Delaware Street Capital Master Fund, L.P. (“DSC” and, collectively with the Deerfield Lenders, the “December 2019 Holders”). Under the December 2019 Exchange Agreement, the Company issued senior secured convertible promissory notes under the Deerfield Facility Agreement in the aggregate principal amount of approximately $71.4 million (the “December 2019 Notes”), in exchange for the cancellation of an aggregate of approximately $71.4 million principal amount and accrued interest of the Company’s 2021 Notes. Upon entering into the December 2019 Exchange Agreement, the Company agreed to pay the December 2019 Holders, in the aggregate, an interest payment of approximately $0.7 million which represents 50% of the accrued interest, as of December 18, 2019, on the 2021 Notes owned by the December 2019 Holders. The remainder of such interest was included in the principal amount of the December 2019 Notes.

The December 2019 Notes bore interest at 6.75% per annum. The December 2019 Notes were convertible into shares of the Company’s common stock at an initial conversion price of $17.11 per share (which represented the conversion price of the 2021 Notes), subject to adjustment in accordance with the terms of the December 2019 Notes. After giving effect to the Reverse Stock Split effected in December 2020, the conversion price of the December 2019 Notes would have been $273.76 per share. The Company subsequently amended the December 2019 Notes to provide that such notes would have been convertible into shares of the Company’s common stock at a conversion price of $93.60 per share (which represented the conversion price of the Deerfield Convertible Note). The conversion price of the December 2019 Notes would have been adjusted downward if the Company issued or sold any shares of common stock, convertible securities, warrants or options at a sale or exercise price per share less than the greater of the December 2019 Notes’ conversion price or the closing sale price of the Company’s common stock on the last trading date immediately prior to such issuance, or, in the case of a firm commitment underwritten offering, on the date of execution of the underwriting agreement between the Company and the underwriters for such offering. However, if the Company effected an “at the market offering” as defined in Rule 415 of the Securities Act, of its common stock, the conversion price of the December 2019 Notes would have been adjusted downward pursuant to this anti-dilution adjustment only if such sales were made at a price less than $93.60 per share, provided that this anti-dilution adjustment would not have applied to any sales made under (x) the 2020 ELOC Agreement, (y) the ATM Agreement, or (z) the September 2019 Exchange Agreement (as amended). Notwithstanding anything to the contrary in the December 2019 Notes, the anti-dilution adjustment of such notes would not have resulted in the conversion price of the December 2019 Notes being less than $9.328 per share. The December 2019 Notes were convertible at any time at the option of the holders thereof, provided that a holder of a December 2019 Note was prohibited from converting such note into shares of the Company’s common stock if, as a result of such conversion, such holder (together with certain affiliates and “group” members) would have beneficially owned more than 4.985% of the total number of shares of common stock then issued and outstanding. However, the December 2019 Note issued to DSC, due to the fact DSC was a beneficial owner of more than 4.985% of the total number of shares of the Company’s common stock then issued and outstanding, had a beneficial ownership cap equal to 19.985% of the total number of shares of the Company’s common stock then issued and outstanding. Pursuant to the December 2019 Notes, the December 2019 Holders had the option to demand repayment of all outstanding principal, and any unpaid interest accrued thereon, in connection with a Major Transaction (as defined in the December 2019 Notes), which included, among others, any acquisition or other change of control of the Company; a liquidation, bankruptcy or other dissolution of the Company; or if at any time after March 31, 2021, shares of the Company’s common stock are not listed on an Eligible Market (as defined in the December 2019 Notes). The December 2019 Notes were subject to specified events of default, the occurrence of which would have entitled the December 2019 Holders to immediately demand repayment of all outstanding principal and accrued interest on the December 2019 Notes. Such events of default included, among others, failure to make any payment under the December 2019 Notes when due, failure to observe or perform any covenant under the Deerfield Facility Agreement (as defined below) or the other transaction documents related thereto (subject to a standard cure period), the failure of the Company to be able to pay debts as they come due, the commencement of bankruptcy or insolvency proceedings against the Company, a material judgement levied against the Company and a material default by the Company under the Deerfield Warrant, the December 2019 Notes or the Deerfield Convertible Note.

The December 2019 Exchange Agreement amended the Deerfield Facility Agreement in order to, among other things, (i) provide for the Deerfield Facility Agreement to govern the December 2019 Notes received by the December 2019 Holders pursuant to the December 2019 Exchange Agreement, (ii) extend the maturity of the Deerfield Convertible Note from February 14, 2020 and June 1, 2020, as applicable, to March 31, 2021, (iii) defer interest payments on the Deerfield Convertible Note until March 31, 2021 (which such interest shall accrue as “payment-in-kind” interest), (iv) designate DSC as a Lender under (and as defined in the Deerfield Facility Agreement), (v) name Deerfield as the “Collateral Agent” for all Lenders and (vi) modify the terms and conditions under which the Company may issue additional pari passu and subordinated indebtedness under the Deerfield Facility Agreement (subject to certain conditions specified in the Deerfield Facility Agreement).

The December 2019 Exchange Agreement also amended and restated the Deerfield Convertible Note to conform the definitions of “Eligible Market” and “Major Transactions” to the definition in the December 2019 Notes, to remove provisions that were only applicable prior to the Company’s initial public offering and to make certain other changes to conform to the December 2019 Notes. The conversion price for the Deerfield Convertible Note remained $93.60 per share, subject to adjustment on the same basis as the December 2019 Notes.

The December 2019 Exchange Agreement also amended the Deerfield Warrant to conform the definitions of “Eligible Market” and “Major Transaction” in the Deerfield Warrant with the definitions of such terms in the December 2019 Notes.

The December 2019 Exchange Agreement contained customary representations, warranties and covenants made by the Company and the December 2019 Holders, including a covenant of the Company to, upon request, use commercially reasonable efforts to use its technology to discover a product based upon a compound that may be identified by the Deerfield Lenders in a manner that is reasonably acceptable to the Deerfield Lenders, or one of their affiliates, with the terms of such discovery plan, including the Company’s compensation thereunder, to be mutually agreed to by the parties.

In connection with entering into the December 2019 Exchange Agreement, on December 18, 2019, the Company amended and restated that certain Guaranty and Security Agreement, dated June 2, 2014, by and between the Company and the other parties thereto (the “GSA”) to, among other things, (i) provide that all of the notes will be secured by the liens securing the indebtedness under the Deerfield Facility Agreement, and (ii) name Deerfield as the “Collateral Agent” under the GSA.

In connection with entering into the December 2019 Exchange Agreement, the Company also entered into an amendment (the “September 2019 Exchange Agreement Amendment”) to the September 2019 Exchange Agreement to, among other things, (i) amend and restate Annex I of the September 2019 Exchange Agreement to allow the Deerfield Lenders to effect optional exchanges of the December 2019 Notes and the Deerfield Convertible Note under the terms of the September 2019 Exchange Agreement; (ii) amend the common stock exchange price under the September 2019 Exchange Agreement to be a per share price equal to the greater of (x) $0.60, subject to adjustment to reflect stock splits and similar events, or (y) the average of the volume-weighted average prices of the Company’s common stock on each of the 15 trading days immediately preceding such exchange, (iii) provide that no more than 28,439,015 of shares of the Company’s common stock shall be issued pursuant to optional exchanges under the September 2019 Exchange Agreement (whether by common stock exchange or upon conversion of Series B-2 Shares (as defined in the September 2019 Exchange Agreement Amendment)), subject to adjustment to reflect stock splits and similar events and (iv) eliminate limitations regarding the timing and aggregate amount of principal which may be exchanged under the September 2019 Exchange Agreement. These changes in the September 2019 Exchange Agreement Amendment significantly modified the Optional Exchange Principal Amount, as such after giving effect to the September Exchange Agreement Amendment the Optional Exchange Principal Amount ceases to exist the new optional exchanges are referred to as the Deerfield Optional Conversion Feature. After giving effect to the Reverse Stock Split effected in December 2020, the exchange price of the Deerfield Optional Conversion Feature would have been $9.60 per share or the average of the volume-weighted average price of the common stock on the principal securities exchange or trading market on which the common stock is then trading on each of the 15 trading days immediately preceding such exchange and the shares of the Company’s common stock issued pursuant to the optional exchanges would have been 1,777,437 shares of common stock.

In connection with entering into the September 2019 Amendment, the Company filed an amendment to the Series B-2 Certificate of Designation (the “Series B-2 Certificate of Designation Amendment”) with the Secretary of State of the State Delaware. The Series B-2 Certificate of Designation Amendment provides that each share of the Company’s Series B-2 preferred stock is convertible into shares of the Company’s common stock at a per share price equal to the common stock exchange price under the September 2019 Exchange Agreement, which equals the greater of (i) $9.60 (subject to adjustment to reflect stock splits and similar events), or (ii) the average of the volume-weighted average prices of the Company’s common stock on each of the 15 trading days immediately preceding such exchange.

As of September 30, 2020, the Deerfield Lenders had converted all $17.1 million of principal under the December 2019 Notes into all 1,777,437 shares of common stock available under the Deerfield Optional Conversion Feature.

The Company determined the changes to the Deerfield Convertible Note met the definition of a troubled debt restructuring under ASC 470-60, Troubled Debt Restructurings by Debtors, as the Company was experiencing financial difficulties and Deerfield granted a concession. The amendments to the terms of the Deerfield Convertible Note resulted in no gain on restructuring because the total cash outflows required under the amended Deerfield Convertible Note exceeded the carrying value of the original Deerfield Convertible Note immediately prior to amendment. Prospectively, the Deerfield Convertible Note will continue to be carried net of the associated discount and debt issuance costs which will be amortized and recorded as interest expense using a modified effective interest rate based on the amendments.

The changes to the 2021 Notes, under the December 2019 Exchange Agreement, referred to after as the December 2019 Notes, were accounted for as a debt modification, prospectively, the December 2019 Notes will be carried net of the associated discount and debt issuance costs which will be amortized and recorded as interest expense using a modified effective interest rate based on the amendments.

2021 Note Exchange Effected in January 2020

In January 2020, the Company entered into the January 2020 Exchange Agreement (the “January 2020 Exchange Agreement”) with M. Kingdon Offshore Master Fund, LP (“Kingdon”). Under the January 2020 Exchange Agreement, the Company issued a senior secured convertible note in the aggregate principal amount of approximately $3.0 million (the “January 2020 Note”) in exchange for the cancellation of an aggregate of $3.0 million principal amount and accrued interest of the 2021 Note then owned by Kingdon. Upon entering into the January 2020 Exchange Agreement, the Company agreed to pay Kingdon an interest payment of approximately $37,000, which represents 50% of the accrued and unpaid interest, as of January 13, 2020, on Kingdon’s 2021 Note. The remainder of such interest was included in the principal amount of the January 2020 Note.

The January 2020 Note was issued with substantially the same terms and conditions as the December 2019 Notes (as amended by the amendment described in more detail below).

In connection with entering into the January 2020 Exchange Agreement, the Company entered into an Amendment to Facility Agreement and December 2019 Notes and Consent (the “December 2019 Note Amendment”) with the December 2019 Holders that, among other things, (i) amended the December 2019 Notes to (a) reduce the Conversion Price (as defined in the December 2019 Notes) from $17.11 to $5.85 per share and (b) increased the Floor Price (as defined in the December 2019 Notes) from $0.38 to $0.583 per share, and (ii) amended the Deerfield Facility Agreement to (x) provide for Kingdon to join the Deerfield Facility Agreement as a Lender (as defined in the Deerfield Facility Agreement) and (y) provide that the 2020 Note and shall constitute a “Senior Secured Convertible Note” (as defined in the Deerfield Facility Agreement) for purposes of the Deerfield Facility Agreement and other Transaction Documents (as defined in the Deerfield Facility Agreement). After giving effect to the Reverse Stock Split effected in December 2020, the Conversion Price became $93.60 per share and the Floor Price became $9.328 per share.

The changes to the 2021 Note, under the January 2020 Exchange Agreement, referred to after as the January 2020 Note, were accounted for as a debt modification, prospectively, the January 2020 Note will be carried net of the associated discount and debt issuance costs which will be amortized and recorded as interest expense using a modified effective interest rate based on the amendments.

December 2020 Exchange Agreement and Amendment to Facility Agreement, Notes and Investors’ Rights Agreement

In December 2020, the Company entered into a December 2020 Exchange Agreement and Amendment to Facility Agreement, Notes and Investors’ Rights Agreement, as amended (the “December 2020 Exchange Agreement”) with the Deerfield Lenders, DSC and Kingdon (collectively, the “Facility Agreement Note Holders”). Under the December 2020 Exchange Agreement, the Company and the Facility Agreement Note Holders agreed that (a) the Company will make a cash pre-payment of a portion of principal amount of the Deerfield Convertible Note, the December 2019 Notes and the January 2020 Note (collectively, the “Facility Agreement Notes”) to the Facility Agreement Note Holders (the “Debt Payment”) equal to approximately $30.3 million, plus accrued interest if such payment is made on or after January 1, 2021, and (b) subject to the satisfaction or waiver of certain conditions specified in the December 2020 Exchange Agreement, including the making of the Debt Payment, issue shares of its Series B-2 Preferred Stock and warrants exercisable for shares of its common stock (the “Exchange Warrants”), in exchange for the cancellation of a portion of the principal amount of the Facility Agreement Notes owned by the Facility Agreement Note Holders in an aggregate amount equal to the Debt Payment, plus the Q4 PIK Interest Payment (as defined in the December 2020 Exchange Agreement) (such transaction, the “December 2020 Exchange”).

The December 2020 Exchange Agreement amended the Facility Agreement Notes to provide that the failure of the Company’s common stock to remain listed on an eligible securities market will not constitute a “Major Transaction” unless such failure occurs after March 31, 2023.

Subject to the satisfaction or waiver of certain conditions specified in the December 2020 Exchange Agreement, including the making of the Debt Payment and the consummation of the exchange, the December 2020 Exchange Agreement amended that certain Facility Agreement dated as of June 2, 2014, as amended (the “Facility Agreement”), by and among the Company and the Facility Agreement Note Holders in order to, among other things, (i) extend the maturity date of the Facility Agreement Notes to March 31, 2023, (ii) provide for cash payments of interest on the Loans (as defined in the Facility Agreement) for the periods following July 1, 2021, and (iii) provide for specified prepayment terms on the Loans.

The December 2020 Exchange Agreement amended that certain Amended and Restated Investors’ Rights Agreement, dated as of February 19, 2015 (the “IRA”), by and among the Company, Deerfield and the other parties signatory thereto in order to, among other things, add Deerfield Special Situations Fund, L.P. as a party thereto and to give effect to the issuance of the Exchange Warrants and the Company’s registration obligations under the December 2020 Exchange Agreement (as described in more detail below).

The Exchange Warrants issued pursuant to the December 2020 Exchange Agreement were exercisable for a number of shares of the Company’s common stock equal to 75% of the shares of common stock issuable upon conversion of the Series B-2 Preferred Stock issued in the Exchange (without regard for any beneficial ownership limitations included therein). The Exercise Warrants were subject to substantially the same terms and conditions as the warrants issued to the public in the public offering of the Company’s securities contemplated pursuant to a registration statement on Form S-1 (File No. 333-250945) (the “Public Offering”), with an exercise price equal to the exercise price per share of the warrants issued in the Public Offering and provided that the Facility Agreement Note Holders will be limited from exercising such Exchange Warrants if, as a result of such exercise, such holders (together with certain affiliates and “group” members of such holders) would beneficially own more than 4.985% of the total number of shares of the Company’s common stock then issued and outstanding.

In anticipation of the Public Offering, and to meet the Nasdaq Listing Requirements, the Company agreed in December 2020 to restructure the December 2019 Notes and the January 2020 Note in the aggregate principal amount of $60.8 million and the Deerfield Note in the principal amount of $7.5 million (collectively the "the Facility Notes"). The total outstanding principal and accrued interest under the Facility Notes was $69.4 million as of December 31, 2020.

Under the terms of the December 2020 Exchange Agreement, the Company, on January 12, 2021, in connection with the closing of the Public Offering:

	●	Exchanged $31.5 million of the outstanding principal and accrued interest on the Facility Notes for (i) 31,476.98412 shares of Series B-2 Preferred Stock, and (ii) Exchange Warrants exercisable for 3,632,019 shares of the Company's common stock, and

	●	Made a payment of $30.3 million (the "Debt Payment"), in partial repayment of the remaining outstanding principal and accrued interest of the Facility Notes.

Following the completion of these transactions, the aggregate balance of principal and accrued interest remaining outstanding under the Facility Notes was approximately $7.6 million. With respect to this remaining outstanding balance under the Facility Notes, the December 2020 Exchange Agreement amended the terms of that debt to provide that:

	●	The maturity date was amended to March 31, 2023, and the debt was prepayable upon specified conditions, and

	●	Interest would accrue at the rate of 6.75% per annum, payable quarterly, would be added to principal until June 30, 2021, and then be payable in cash thereafter.

The changes to the Facility Notes, under the December 2020 Exchange Agreement, were accounted for as a debt extinguishment as the cash flows immediately after the December 2020 Exchange Agreement were substantially different from the cash flows immediately prior to the December 2020 Exchange Agreement and while the Company was experiencing financial difficulties it was determined that the lender did not grant a concession. As such, a loss of extinguishment related to the extinguishment of the old notes is recorded in the statement of operations for the year ended December 31, 2021, and additional debt issuance costs related the new notes were capitalized and amortized using the effective interest method through the Payoff of Facility Agreement Notes (discussed below).

The transactions contemplated under the December 2020 Exchange Agreement, including the obligation to pre-pay any portion of the Facility Agreement Notes or to complete the Exchange and the effectiveness of the amendments to the Facility Agreement, the Notes and the IRA, were subject to specified conditions of closing, including certain closing of the Public Offering, the filing of the Restated Series B-2 Certificate of Designation (as defined below) and the approval for listing of the Company’s common stock, including the shares issuable upon conversion of the Series B-2 Preferred Stock and exercise of the Exchange Warrants, on the Nasdaq Capital Market.

As a condition to closing of the December 2020 Exchange Agreement, the Company filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Convertible Preferred Stock (the “Restated Series B-2 Certificate of Designation”) with the Secretary of State of the State Delaware, setting forth the preferences, rights and limitations of the Series B-2 Preferred Stock.

Each share of Series B-2 Preferred Stock had an aggregate stated value of $1,000 and was convertible into shares of the Company’s common stock at a per share price equal to the price per share to the public of the Company’s common stock in the Public Offering (subject to adjustment to reflect stock splits and similar events).

The Series B-2 Preferred Stock was convertible at any time on or after the PDUFA Date (as defined in the Restated Series B-2 Certificate of Designation) at the option of the holders thereof; provided that the holders thereof will be prohibited from converting shares of Series B-2 Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, such holders (together with certain affiliates and “group” members of such Holders) would beneficially own more than 4.985% of the total number of shares of the Company’s common stock then issued and outstanding. The Series B-2 Preferred Stock is not redeemable. In the event of the Company’s liquidation, dissolution or winding up or a change in control of the Company (each, a “Liquidation Event”), the holders of Series B-2 Preferred Stock will receive, prior to any distribution or payment on our common stock, an amount equal to the greater of (i) $1,000 per share (in the case of a change in control, transaction consideration with such value), or (ii) the amount (in the case of a change in control, in the form of the transaction consideration) per share each such holder would have been entitled to receive if every share of Series B-2 Preferred Stock had been converted into common stock immediately prior to such Liquidation Event, in each case, plus any declared but unpaid dividends thereon. With respect to rights upon liquidation, the Series B-2 Preferred Stock ranks senior to the common stock, on parity with any Parity Securities (as defined in the Restated Series B-2 Certificate of Designation) and junior to existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions involving the Company’s organizational documents that adversely affect the holders of Series B-2 Preferred Stock and other specified matters regarding the rights, preferences and privileges of the Series B-2 Preferred Stock), the Series B-2 Preferred Stock does not have voting rights. The Series B-2 Preferred Stock is not subject to any price-based anti-dilution protections and does not provide for any accruing dividends but provides that holders of Series B-2 Preferred Stock will participate in any dividends on the Company’s common stock on an as-converted basis (without giving effect to the limitation on conversion described above). The Restated Series B-2 Certificate of Designation also provides for partial liquidated damages in the event that the Company fails to timely convert shares of Series B-2 Preferred Stock into common stock in accordance with the Restated Series B-2 Certificate of Designation.

Payoff of Facility Agreement Notes and Termination of Facility Agreement

On February 8, 2021, the Company entered into a payoff letter with the Facility Agreement Note Holders, pursuant to which the Company agreed to pay off and thereby terminate the Facility Agreement.

Pursuant to the payoff letter, the Company paid a total of $8.0 million to the Facility Agreement Note Holders, representing the principal balance, accrued interest outstanding and a prepayment fee in repayment of the Company’s outstanding obligations under the Facility Agreement.

Pursuant to the payoff letter, all outstanding indebtedness and obligations of the Company owing to the Facility Agreement Note Holders under the Facility Agreement have been paid in full. The Facility Agreement and the notes thereunder, as well as the security interests in the assets of the Company securing the Facility Agreement and note obligations, have been terminated. The Facility Agreement Note Holders will retain the warrants previously issued to them by the Company.

The Company determined the payoff letter met the liability derecognition threshold under ASC 405-20, Liabilities - Extinguishment of Liabilities, as the Company repaid the debt (and has been relieved of the related obligation) without entering into new debt with the Facility Agreement Note Holders and there is no other continuing debt with the Facility Agreement Note Holders. The payoff letter resulted in a loss on extinguishment of debt which is shown within other (expense) income in the statements of operations for the year ended December 31, 2021.

PPP Loan

On April 23, 2020, the Company received proceeds of $0.8 million from the PPP Loan under the PPP of the CARES Act, a portion of which may be forgiven, which the Company used to retain current employees, maintain payroll and make lease and utility payments. In May 2021, the Company received notice from the U.S. Small Business Administration that the principal and interest due under its PPP Loan had been forgiven in full. This gain on extinguishment is shown, net of the loss on extinguishment of debt discussed above, within other (expense) income in the statements of operations for the year ended December 31, 2021.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Note A - Description of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2021

Business Description and Basis of Presentation [Text Block]

A.	Description of Business and Basis of Presentation

Organization

KemPharm, Inc. (the "Company") is a specialty pharmaceutical company focused on the discovery and development of treatments for central nervous system ("CNS") and rare disease indications that allow the Company to target high-value areas with significant unmet needs. The Company's core competency is the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary Ligand Activated Therapy ("LAT^®") platform technology. The Company utilizes its proprietary LAT platform technology to generate improved prodrug versions of drugs approved by the U.S. Food and Drug Administration ("FDA") as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. The Company's prodrug product candidate pipeline is currently focused on the high need areas of idiopathic hypersomnia ("IH") and other CNS/rare diseases. The Company's approved product, AZSTARYS^®, formerly referred to as KP415, a new once-daily treatment for attention deficit hyperactivity disorder ("ADHD") in patients age six years and older contains the Company's prodrug, serdexmethylphenidate ("SDX"). AZSTARYS is being commercialized in the United States by Corium, Inc., an affiliate of Gurnet Point Capital, L.P. The Company's lead clinical development product candidate, KP1077, is based on SDX, the Company's prodrug of d-methlyphenidate ("d-MPH") and is in development for the treatment of IH and narcolepsy. The Company's prodrug product candidate for the treatment of stimulant use disorder ("SUD") is KP879.

Basis of Presentation

The Company prepared the financial statements in accordance with United States generally accepted accounting principles (“GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (the "SEC") and, in the Company's opinion, reflect all adjustments, including normal recurring items that are necessary.

Reverse Stock Split

On December 23, 2020, the Company completed a one-for-sixteen reverse stock split (the “Reverse Stock Split”), which reduced the number of shares of the Company’s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse Stock Split. The number of shares of the Company’s authorized common stock was not affected by the Reverse Stock Split and the par value of the Company’s common stock remained unchanged at $0.0001 per share. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise held fractional shares of the Company’s common stock as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. Except where disclosed, all amounts related to number of shares and per share amounts have been retroactively restated in these financial statements to reflect this Reverse Stock Split.

Entry into 2020 ELOC Agreement

In February 2020, the Company entered into a purchase agreement for an equity line of credit (the “2020 ELOC Agreement”) with Lincoln Park Capital, LLC ("Lincoln Park") which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company may sell to Lincoln Park up to $4.0 million of shares of common stock from time to time over the 12-month term of the 2020 ELOC Agreement, and upon execution of the 2020 ELOC Agreement the Company issued an additional 19,289 shares of common stock to Lincoln Park as commitment shares in accordance with the closing conditions within the 2020 ELOC Agreement. Concurrently with entering into the 2020 ELOC Agreement, the Company also entered into a registration rights agreement with Lincoln Park (the “2020 ELOC Registration Rights Agreement”) pursuant to which the Company agreed to register the sale of the shares of common stock that have been and may be issued to Lincoln Park under the 2020 ELOC Agreement pursuant to the Company’s existing shelf registration statement on Form S-3 or a new registration statement. In May 2020, the Company reached the maximum allowable shares to be issued under the registration statement of 579,260 shares (inclusive of the 19,289 commitment shares) as defined in Section 2(f)(i) of the 2020 ELOC Agreement and therefore cannot issue additional shares under the 2020 ELOC Agreement. Through May 2020, the Company sold 559,971 shares of common stock to Lincoln Park (exclusive of the 19,289 commitment shares) under the 2020 ELOC Agreement for gross proceeds of approximately $2.3 million.

Underwriting Agreement

On January 8, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC (the “Underwriter” or "Roth"), to issue and sell 6,765,463 shares of common stock of the Company, pre-funded warrants to purchase 926,844 shares of common stock and warrants to purchase 7,692,307 shares of common stock at an exercise price per share of $6.50 in an underwritten public offering (the “Public Offering”) pursuant to a registration statement on Form S-1 (File No. 333-250945) and a related prospectus, in each case filed with the Securities and Exchange Commission (the “SEC”). The offering price to the public was $6.50 per share of common stock and accompanying warrant, representing a public offering price of $6.4999 per share of common stock and $0.0001 per related warrant. In addition, the Company granted the Underwriter an option to purchase, for a period of 45 days, up to an additional 1,153,846 shares of the Company’s common stock and/or warrants to purchase up to an additional 1,153,846 shares of the Company’s common stock.

On January 8, 2021, the Underwriter exercised its over-allotment option, in part, for warrants to purchase 754,035 shares of the Company’s common stock. Further on February 1, 2021, the Underwriter again exercised its over-allotment option to purchase 374,035 shares of common stock.

On January 12, 2021, the Company closed the Public Offering. The aggregate gross proceeds to the Company from the Public Offering, including over-allotment, totaled approximately $52.4 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.

On January 25, 2022, the Company filed an amendment to the registration statement on Form S-1 (File No. 333-250945) on Form S-3 covering the issuance of the shares of our common stock issuable upon the exercise of the warrants issued in the Public Offering and remaining unexercised as of the date of the amendment, which was declared effective on February 1, 2022.

Listing on the Nasdaq Stock Market

On January 7, 2021, the Company’s common stock was approved for listing on the Nasdaq Capital Market. The Company’s common stock began trading on the Nasdaq Capital Market on January 8, 2021, under the ticker symbol “KMPH”.

On October 19, 2021, the Company announced that its shares of common stock were approved for listing to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market commenced effective with the open of business on October 19, 2021, under the Company’s ticker symbol, “KMPH”. The Company was previously listed on the Nasdaq Capital Market, following its uplisting to the exchange in January 2021.

Entry into 2021 ATM Agreement

On July 2, 2021, the Company entered into an equity distribution agreement (the "2021 ATM Agreement") with JMP Securities LLC ("JMP") and RBC Capital Markets, LLC ("RBCCM") under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through JMP and RBCCM as its sales agents. The issuance and sale, if any, of common stock by the Company under the 2021 ATM Agreement will be made pursuant to a registration statement on Form S-3. JMP and RBCCM may sell the common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended. JMP and RBCCM will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay JMP and RBCCM a commission equal to 3.0% in the aggregate of the gross sales proceeds of any common stock sold through JMP and RBCCM under the 2021 ATM Agreement. The Company filed a registration statement on Form S-3 covering the sale of the shares of its common stock up to $350.0 million, $75.0 million of which was allocated to the sales of the shares of common stock issuable under the 2021 ATM Agreement, which was declared effective on July 12, 2021. As of December 31, 2021, no shares have been issued or sold under the 2021 ATM Agreement.

Share Repurchase Program

On December 20, 2021, the Company initiated a share repurchase program (the "Share Repurchase Program") pursuant to which the Company may repurchase up to $50 million of shares of its common stock through December 31, 2023. Capital allocation to the Share Repurchase Program will be based on a variety of factors, including our business results, the receipt of royalties and sales milestones under the KP415 License Agreement, and potentially other sources of non-dilutive capital that may become available to the Company. Repurchases will be made in compliance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended, subject to a variety of factors, including the market price of the Company’s common stock, general market and economic conditions and applicable legal requirements. The exact number of shares to be repurchased by the Company is not guaranteed and the program may be suspended, modified, or discontinued at any time without prior notice. As of December 31, 2021, the Company has repurchased 320,161 shares of its common stock for approximately $2.8 million under the Share Repurchase Program.

Note P - Severance Expense

12 Months Ended

Dec. 31, 2021

Restructuring and Related Activities Disclosure [Text Block]

P.	Severance Expense

In February 2020, the Company eliminated the chief business officer role. In connection with the elimination, the chief business officer was entitled to severance benefits as documented in his Amended and Restated Employment Agreement entered into in June 2015. The severance benefits consisted of personnel and other related charges of approximately $0.4 million and stock compensation expense of approximately $0.4 million related to the acceleration of vesting on unvested shares subject to certain stock options. These severance benefits are presented as severance expense in the statements of operations for the year ended December 31, 2020. As of December 31, 2020, the Company had accrued severance expense recorded within accounts payable and accrued expenses in the amount of $0.1 million. For the year ended December 31, 2021, there was no severance expense. As of December 31, 2021, there was no accrued severance expense.

Note J - Preferred Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended		9 Months Ended	12 Months Ended
	Jan. 12, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Preferred Stock, Shares Authorized (in shares)					10,000,000	10,000,000
Preferred Stock, Shares Issued, Total (in shares)					0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0
Debt Conversion, Converted Instrument, Shares Issued (in shares)				1,777,437
Conversion of Series B-2 Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)			4,842,699		4,842,699
The Facility Notes [Member]
Repayments of Long-term Debt, Total	$ 30.3
December 2020 Exchange Agreement [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,476.98412
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)	3,632,019
Debt Conversion, Original Debt, Amount	$ 31.5
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)		9,578				9,578
Preferred Stock, Shares Issued, Total (in shares)						9,577
Preferred Stock, Shares Outstanding, Ending Balance (in shares)						0
Series B-1 Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)					0	1,576
Preferred Stock, Shares Issued, Total (in shares)		1,576			0	1,576
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0	0
Series B-2 Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)					0	27,000
Preferred Stock, Shares Issued, Total (in shares)					0	27,000
Preferred Stock, Shares Authorized, Elimated (in shares)		31,480
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0	0
Preferred Stock, Convertible, Shares Issuable (in shares)	4,842,690
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 6.4999

Note L - Stock-based Compensation - Information Regarding Currently Outstanding and Exercisable Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Options outstanding, number of shares (in shares)	1,273,879	355,785
Outstanding, weighted average remaining contractual term (Year)	8 years 8 months 23 days	7 years 4 months 2 days
Exercisable, number of options (in shares)	307,215
Exercisable, weighted average remaining contractual term (Year)	6 years 3 months 7 days
Exercise Price Range One [Member]
Lower range (in dollars per share)	$ 2.848
Upper range (in dollars per share)	$ 10.00
Options outstanding, number of shares (in shares)	976,833
Outstanding, weighted average remaining contractual term (Year)		9 years 5 months 19 days
Exercisable, number of options (in shares)	115,694
Exercisable, weighted average remaining contractual term (Year)		8 years 21 days
Exercise Price Range Two [Member]
Lower range (in dollars per share)	$ 10.01
Upper range (in dollars per share)	$ 30.00
Options outstanding, number of shares (in shares)	69,375
Outstanding, weighted average remaining contractual term (Year)	9 years 2 months 1 day
Exercisable, number of options (in shares)	9,375
Exercisable, weighted average remaining contractual term (Year)	7 years 3 months 21 days
Exercise Price Range Three [Member]
Lower range (in dollars per share)	$ 30.01
Upper range (in dollars per share)	$ 50.00
Options outstanding, number of shares (in shares)	72,404
Outstanding, weighted average remaining contractual term (Year)	7 years 1 month 9 days
Exercisable, number of options (in shares)	36,214
Exercisable, weighted average remaining contractual term (Year)	7 years 1 month 9 days
Exercise Price Range Four [Member]
Lower range (in dollars per share)	$ 50.01
Upper range (in dollars per share)	$ 70.00
Options outstanding, number of shares (in shares)	44,365
Outstanding, weighted average remaining contractual term (Year)	5 years 29 days
Exercisable, number of options (in shares)	44,365
Exercisable, weighted average remaining contractual term (Year)	5 years 29 days
Exercise Price Range Five [Member]
Lower range (in dollars per share)	$ 70.01
Upper range (in dollars per share)	$ 327.20
Options outstanding, number of shares (in shares)	110,902
Outstanding, weighted average remaining contractual term (Year)	4 years 6 months
Exercisable, number of options (in shares)	101,567
Exercisable, weighted average remaining contractual term (Year)	4 years 4 months 6 days

Note L - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 30, 2021	Dec. 31, 2020
Stock based compensation expense	$ 2,436	$ 2,491
Research and Development Expense [Member]
Stock based compensation expense	914	937
General and Administrative Expense [Member]
Stock based compensation expense	1,522	1,134
Severance Expense [Member]
Stock based compensation expense	$ 0	$ 420

Note L - Stock-based Compensation

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Text Block]

L.	Stock-Based Compensation

The Company maintains a stock-based compensation plan (the “Incentive Stock Plan”) that governs stock awards made to employees and directors prior to completion of the IPO.

In November 2014, the Board of Directors of the Company ("the Board"), and in April 2015, the Company’s stockholders, approved the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), which became effective in April 2015. The 2014 Plan provides for the grant of stock options, other forms of equity compensation, and performance cash awards. In June 2021, the Company's stockholders approved an Amended and Restated 2014 Equity Incentive Plan (the "A&R 2014 Plan"), following its adoption by the Board in April 2021, which among other things added 4,900,000 shares to the maximum number of shares of common stock to be issued under the plan and extended the annual automatic increases (discussed further below) until January 1, 2031 and eliminated individual grant limits that applied under the 2014 Plan to awards that were intended to comply with the exemption for "performance-based compensation" under Code Section 162(m). The maximum number of shares of common stock that may be issued under the A&R 2014 Plan is 5,489,660 as of December 31, 2021. The number of shares of common stock reserved for issuance under the A&R 2014 Plan will automatically increase on January 1 of each year, beginning on January 1, 2016, and ending on and including January 1, 2031, by 4% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Board. Pursuant to the terms of the 2014 Plan, on January 1, 2022, the common stock reserved for issuance under the 2014 Plan automatically increased by 1,400,225 shares.

During 2020, the Company granted to certain consultants fully vested restricted stock awards (“RSAs”) under the 2014 Plan. The RSAs were granted as compensation in accordance with each consultant's consulting agreement for services performed during 2020. For the year ended December 31, 2020, RSAs were granted for a total of 10,247 shares of common stock. No RSAs were granted during the year ended December 31, 2021.

During the year ended December 31, 2020, stock options to acquire 279 shares of common stock were exercised for approximately $2,000 with an intrinsic value of approximately $1,000. During the year ended December 31, 2021 no stock options were exercised.

Stock-based compensation expense recorded under the Incentive Stock Plan, 2014 Plan and A&R 2014 Plan is included in the following line items in the accompanying statements of operations (in thousands):

	*Year ended December 31,*
	*2021*		*2020*
Research and development	$	914	$	937
General and administrative		1,522		1,134
Severance expense		-		420
Total stock-based compensation expense	$	2,436	$	2,491

Stock Option Awards

The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, which requires the use of subjective assumptions, including the expected term of the option, the expected stock price volatility, expected dividend yield and the risk-free interest rate for the expected term of the option. The expected term represents the period of time the stock options are expected to be outstanding. Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected term of the stock options, the Company uses the simplified method to estimate the expected term for its “plain vanilla” stock options. Under the simplified method, the expected term of an option is presumed to be the mid-point between the vesting date and the end of the contractual term. Some options, for example those that have exercise prices in excess of the fair value of the underlying stock, are not considered “plain vanilla” stock options. For these options, the Company uses an expected term equal to the contractual term of the option. Expected volatility is based on the Company’s historical volatility over the estimated expected term of the stock options. The Company assumes no dividend yield because dividends are not expected to be paid in the near future, which is consistent with the Company’s history of not paying dividends.

The Company recognizes compensation expense related to stock-based payment transactions upon satisfaction of the requisite service or vesting requirements. Forfeitures are estimated at the time of grant and revised based on actual forfeitures, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Using the Black-Scholes option-pricing model, the weighted-average fair value of awards granted during the years ended December 31, 2021, and 2020, fair value was $7.53 and $5.00 per share, respectively. The assumptions used to estimate fair value are as follows:

	*Year Ended December 31,*
	*2021*	*2020*
Risk-free interest rate	0.92% - 1.55%	0.38% - 1.65%
Expected term (in years)	5.50 - 10.00	5.50 - 10.00
Expected volatility	96.91% - 102.57%	89.49% - 93.07%
Expected dividend yield	0	0

The activity under the Incentive Stock Plan, 2014 Plan and A&R 2014 Plan for the year ended December 31, 2021, is summarized as follows:

			*Weighted*		*Weighted Avg*		*Aggregate*
	*Number of*		*Average*		*Remaining*		*Intrinsic*
	*Options*		*Exercise Price*		*Contractual Term*		*Value*
Outstanding balance at January 1, 2021		355,785	$	74.60		7.34	$	543,021
Granted		919,383	$	9.48
Exercised or released		-	$	-
Canceled or forfeited		-	$	-
Expired		1,289	$	93.60
Outstanding balance at December 31, 2021		1,273,879	$	27.58		8.73	$	254,207
Exercisable at December 31, 2021		307,215	$	78.39		6.27	$	247,482
Vested and expected to vest at December 31, 2021		1,163,252	$	29.32		8.64	$	253,798

Information regarding currently outstanding and exercisable options as of December 31, 2021, is as follows:

	Options Outstanding				Options Exercisable
			Weighted Avg				Weighted Avg
	Number of		Remaining		Number of		Remaining
Exercise Price	Shares		Contractual Term		Shares		Contractual Term
$2.848 to $10.00		976,833		9.47		115,694		8.06
$10.01 to $30.00		69,375		9.17		9,375		7.31
$30.01 to $50.00		72,404		7.11		36,214		7.11
$50.01 to $70.00		44,365		5.08		44,365		5.08
$70.01 to $327.20		110,902		4.50		101,567		4.35
		1,273,879		8.73		307,215		6.27

The total fair value of stock options vested during the years ended December 31, 2021, and 2020, was $2.0 million and $3.7 million, respectively.

Unvested stock options as of December 31, 2021, and 2020, were as follows:

	Number of Unvested Shares
	December 31,
Exercise Price	2021		2020
$2.848 to $10.00		861,139		82,247
$10.01 to $30.00		60,000		-
$30.01 to $50.00		36,190		54,300
$50.01 to $70.00		-		9,429
$70.01 to $327.20		9,335		18,675
Total number of unvested stock options		966,664		164,651

As of December 31, 2021, there was $5.8 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2014 Plan and A&R 2014 Plan. That compensation cost is expected to be recognized over a weighted-average period of 3.17 years.

There was $0.4 million and $0.3 million of stock-based compensation expense related to performance-based awards recognized during the years ended December 31, 2021, and 2020, respectively.

Note R - Subsequent Events (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 29, 2022	Dec. 31, 2021
Treasury Stock, Value, Acquired, Cost Method		$ 2,814
Subsequent Event [Member]
Treasury Stock, Shares, Acquired (in shares)	589,792
Treasury Stock, Value, Acquired, Cost Method	$ 4,700

Note K - Common Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) - shares	Dec. 31, 2021	Dec. 31, 2020
Common shares reserved for future issuance (in shares)	11,236,414	1,296,515
Warrant [Member]
Common shares reserved for future issuance (in shares)	4,252,600	151,442
Share-based Payment Arrangement [Member]
Common shares reserved for future issuance (in shares)	1,273,879	355,785
Possible Future Issuances Under Equity Incentive Plans [Member]
Common shares reserved for future issuance (in shares)	4,209,935	0
Possible Future Issuances Under Employee Stock Purchase Plans [Member]
Common shares reserved for future issuance (in shares)	1,500,000	47,825
January 2020 Note [Member]
Common shares reserved for future issuance (in shares)	0	34,615
2021 Notes [Member]
Common shares reserved for future issuance (in shares)	0	625,747
Convertible Notes Payable [Member]
Common shares reserved for future issuance (in shares)	0	81,101

Note L - Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Outstanding, number of options (in shares)	355,785
Outstanding, weighted average exercise price (in dollars per share)	$ 74.60
Outstanding, weighted average remaining contractual term (Year)	8 years 8 months 23 days	7 years 4 months 2 days
Outstanding, aggregate intrinsic value	$ 254,207	$ 543,021
Granted, number of options (in shares)	919,383
Granted, weighted average exercise price (in dollars per share)	$ 9.48
Common stock issued as a result of stock option exercise (in shares)	0
Exercised or released, weighted average exercise price (in dollars per share)	$ 0
Canceled or forfeited, number of options (in shares)	0
Canceled or forfeited, weighted average exercise price (in dollars per share)	$ 0
Expired, number of options (in shares)	1,289
Expired, weighted average exercise price (in dollars per share)	$ 93.60
Outstanding, number of options (in shares)	1,273,879	355,785
Outstanding, weighted average exercise price (in dollars per share)	$ 27.58	$ 74.60
Exercisable, number of options (in shares)	307,215
Exercisable, weighted average exercise price (in dollars per share)	$ 78.39
Exercisable, weighted average remaining contractual term (Year)	6 years 3 months 7 days
Exercisable, aggregate intrinsic value	$ 247,482
Vested and expected to vest, number of options (in shares)	1,163,252
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 29.32
Vested and expected to vest, weighted average remaining contractual term (Year)	8 years 7 months 20 days
Vested and expected to vest, aggregate intrinsic value	$ 253,798

Note N - Income Taxes - Federal Net Operating Loss Carryforward and Research Activities Credit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net Operating Loss Carryforwards	$ 233,279
Research Activities Tax Credit	6,411	$ 6,411
Tax Year 2007 [Member]
Net Operating Loss Carryforwards	454
Research Activities Tax Credit	$ 30
Expiration	2027
Tax Year 2008 [Member]
Net Operating Loss Carryforwards	$ 1,178
Research Activities Tax Credit	$ 65
Expiration	2028
Tax Year 2009 [Member]
Net Operating Loss Carryforwards	$ 3,060
Research Activities Tax Credit	$ 176
Expiration	2029
Tax Year 2010 [Member]
Net Operating Loss Carryforwards	$ 3,423
Research Activities Tax Credit	$ 149
Expiration	2030
Tax Year 2011 [Member]
Net Operating Loss Carryforwards	$ 9,929
Research Activities Tax Credit	$ 176
Expiration	2031
Tax Year 2012 [Member]
Net Operating Loss Carryforwards	$ 0
Research Activities Tax Credit	$ 170
Expiration	2032
Tax Year 2013 [Member]
Net Operating Loss Carryforwards	$ 4,353
Research Activities Tax Credit	$ 133
Expiration	2033
Tax Year 2014 [Member]
Net Operating Loss Carryforwards	$ 15,897
Research Activities Tax Credit	$ 894
Expiration	2034
Tax Year 2015 [Member]
Net Operating Loss Carryforwards	$ 23,496
Research Activities Tax Credit	$ 598
Expiration	2035
Tax Year 2016 [Member]
Net Operating Loss Carryforwards	$ 41,580
Research Activities Tax Credit	$ 745
Expiration	2036
Tax Year 2017 [Member]
Net Operating Loss Carryforwards	$ 34,776
Research Activities Tax Credit	$ 652
Expiration	2037
Tax Year 2018 [Member]
Net Operating Loss Carryforwards	$ 56,099
Research Activities Tax Credit	2,271
Tax Year 2019 [Member]
Net Operating Loss Carryforwards	22,922
Research Activities Tax Credit	352
Tax Year 2020 [Member]
Net Operating Loss Carryforwards	8,784
Research Activities Tax Credit	0
Tax Year 2021 [Member]
Net Operating Loss Carryforwards	7,328
Research Activities Tax Credit	$ 0

Note M - Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

			Quoted Prices		Significant
			in Active		Other		Significant
	*Balance at*		*Markets for*		*Observable*		*Unobservable*
	*December 31,*		*Identical Assets*		*Inputs*		*Inputs*
	*2021*		*(Level 1)*		*(Level 2)*		*(Level 3)*
Deerfield Warrant liability	$	288	$	-	$	-	$	288
Embedded Warrant Put Option		18		-		-		18
KVK Warrant liability		24		-		24		-
Total liabilities	$	330	$	-	$	24	$	306
Trading securities:
U.S. government-sponsored agency securities	$	4,997	$	-	$	4,997	$	-
Certificates of deposit		490		490		-		-
U.S. Treasury securities		9,935		9,935		-		-
Total assets	$	15,422	$	10,425	$	4,997	$	-

			*Quoted Prices*		*Significant*
			*in Active*		*Other*		*Significant*
	*Balance at*		*Markets for*		*Observable*		*Unobservable*
	*December 31,*		*Identical Assets*		*Inputs*		*Inputs*
	*2020*		*(Level 1)*		*(Level 2)*		*(Level 3)*
Deerfield Warrant liability	$	230	$	-	$	-	$	230
Embedded Warrant Put Option		25		-		-		25
Deerfield Note Conversion Feature		-		-		-		-
KVK Warrant liability		49		-		49		-
Total liabilities	$	304	$	-	$	49	$	255

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	*2021*		*2020*
Balance as of beginning of period	$	255	$	96
Adjustment to fair value		51		159
Balance as of end of period	$	306	$	255

Note E - Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Table Text Block]

	*December 31,*
	*2021*			*2020*
Laboratory equipment	$	645		$	643
Furniture and office equipment		71			71
Computers and hardware		338			296
Leasehold improvements		724			724
Finance lease right-of-use assets		1,031			1,031
Total property and equipment		2,809			2,765
Less: accumulated depreciation and amortization		(1,925	)		(1,726	)
Property and equipment, net	$	884		$	1,039

Property, Plant and Equipment, Useful Life [Table Text Block]

		*Useful Life*
Asset Category		*(in years)*
Laboratory equipment		10
Furniture and office equipment		5 - 10
Computers and hardware		3 - 7
Leasehold improvements		9

Note E - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Depreciation, Depletion and Amortization, Total	$ 257,000	$ 273,000

Note J - Preferred Stock and Warrants (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Preferred Stock [Table Text Block]

	Shares Authorized	Shares Issued	Shares Outstanding
Series A convertible preferred stock, $0.0001 par value	9,578	9,577	—
Series B-1 convertible preferred stock, $0.0001 par value	1,576	1,576	—
Series B-2 convertible preferred stock, $0.0001 par value	27,000	27,000	—

Note B - Summary of Significant Accounting Policies (Details Textual) - USD ($)						3 Months Ended				12 Months Ended
	May 07, 2021	Apr. 08, 2021	Mar. 02, 2021	Sep. 03, 2019	Mar. 20, 2012	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Jul. 31, 2020	May 31, 2020
Investments, Fair Value Disclosure, Total										$ 15,400,000
Unrealized Gain (Loss) on Investments, Total										(13,000)
Investments, Total											$ 0
Impairment, Long-Lived Asset, Held-for-Use										0	0
Revenue from Contract with Customer, Including Assessed Tax										28,650,000	13,288,000
Accounts Receivable, after Allowance for Credit Loss, Current, Total										1,421,000	2,442,000
Accounts Receivable, Allowance for Credit Loss, Ending Balance										0	0
Income Tax Examination, Penalties and Interest Accrued										$ 0	0
Income tax returns under examination										0
License [Member]
Deferred Revenue, Total											0
Consulting Services [Member]
Revenue from Contract with Customer, Including Assessed Tax										$ 100,000	1,700,000
Deferred Revenue, Total										0	0
Accounts Receivable, after Allowance for Credit Loss, Current, Total										100,000	400,000
GPC Member \| License [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 10,000,000.0	$ 10,000,000.0	$ 10,000,000.0	$ 10,000,000.0							7,300,000
Revenue Recognition, Milestone Method, Revenue to be Recognized		$ 10,000,000.0		63,000,000.0
Revenue Recognition, Milestone Method, Additional Revenue to be Recognized	$ 590,000,000.0			$ 420,000,000.0
Regulatory Milestone Revenue to Be Earned Following FDA Acceptance													$ 5,000,000.0
Contract with Customer, Liability, Revenue Recognized							$ 10,000,000.0	$ 10,000,000.0	$ 5,000,000.0
Deferred Revenue, Total										0
Accounts Receivable, after Allowance for Credit Loss, Current, Total										100,000
Aquestive Therapeutics [Member] \| License [Member]
Revenue from Contract with Customer, Including Assessed Tax										20,900,000
Royalty Revenue, Percent					10.00%
Royalty Expense							$ 1,000,000.0	$ 1,000,000.0
Corium, Inc [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total										1,200,000	2,100,000
Corium, Inc [Member] \| Consulting Services [Member]
Revenue from Contract with Customer, Including Assessed Tax										7,700,000	3,900,000
Deferred Revenue, Total										$ 400,000	$ 100,000
Consulting Agreement, Maximum Amount to be Received												$ 15,600,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total												13,600,000
Consulting Agreement, Conditional Milestone Achievement to be Received												$ 2,000,000.0
Percentage of Consulting Services and Out-of-pocket Third-party Research and Development Costs Recognized										85.00%
Corium, Inc [Member] \| Consulting Services [Member] \| Forecast [Member]
Revenue from Contract with Customer, Including Assessed Tax						$ 2,000,000.0
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)										3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)										10 years

Note C - Accounts and Other Receivables - Accounts and Other Receivables

12 Months Ended

Dec. 31, 2021